

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<u>http://bmjopen.bmj.com</u>).

If you have any questions on BMJ Open's open peer review process please email <u>info.bmjopen@bmj.com</u>

BMJ Open

BMJ Open

Medication adherence to antithrombotic therapy in patients with peripheral arterial disease: a systematic review

Journal:	BMJ Open
Manuscript ID	bmjopen-2024-085056
Article Type:	Original research
Date Submitted by the Author:	08-Feb-2024
Complete List of Authors:	Wegerif, Emilien; University Medical Centre Utrecht, Vascular surgery Mol, Barend; University Medical Centre Utrecht, Department of Vascular Surgery Ünlü, Çağdaş; Noordwest Ziekenhuisgroep, Vascular surgery de Borst, Gert-Jan; University Medical Centre Utrecht, Vascular Surgery
Keywords:	Medication Adherence, Medication Persistence < Medication Adherence, Medication Review, Systematic Review, Vascular surgery < SURGERY, VASCULAR SURGERY





I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our <u>licence</u>.

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which <u>Creative Commons</u> licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

terez oni

Enseignement Superieur (ABES) Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies



Medication adherence to antithrombotic therapy in patients with peripheral arterial disease: a systematic review

Emilien C. J. Wegerif, MD, MSc^{1A}, Barend Mol, MD^{2A}, Çağdaş Ünlü, MD, Ph.D^{3B}, Gert J. de Borst, MD, Ph.D.^{4A}

Affiliations

- A. University Medical Center Utrecht, Department of Vascular Surgery, Circulatory Health, Heidelberglaan 100, 3584CX, Utrecht, the Netherlands
- B. NoordWest Ziekenhuisgroep, Department of Vascular Surgery, Wilhelminalaan 12, 1815 JD, Alkmaar, the Netherlands

Keywords: Medication Adherence, Treatment Adherence and Compliance, Peripheral Arterial Disease, Platelet Aggregation Inhibitors, Anticoagulants, Systematic Review.

Conflict of interest: None of the authors have any conflicts of interest regarding this article.

Location: This research has been executed at the University Medical Center Utrecht.

Funding: This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.

Competing interest: There is no competing interest.

Correspondence:

Gert J. de Borst, MD, Ph.D. professor of Vascular Surgery, University Medical Center Utrecht, Department of Vascular Surgery, Circulatory Health, Heidelberglaan 100, 3584CX, Utrecht, the Netherlands

Phone number:+31 887556965Email:g.j.deborst-2@umcutrecht.nl

Word count: Abstract: 300 Body: 2100

Strengths and limitations of this study

- This review is based on the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA)-statement and contains a comprehensive search compiled by a medical database specialist.
- Studies regarding medication adherence to antithrombotic therapy in peripheral arterial disease patients are scarce, leading to limited data.
- The included trials had rather heterogeneous study designs, making a metaanalysis infeasible and creating a wide dispersion in medication adherence proportions.
- This review provides insight into the extent of the patient's poor medication adherence.

ABSTRACT

Introduction: Patients with peripheral arterial disease (PAD) have a high risk of atherothrombotic events (AE). Antithrombotic therapy (ATT) is an important component in the treatment armamentarium to prevent AE. Poor medication adherence (MA) may compromise the preventive benefit. Most MA studies primarily concentrate on patients without PAD diagnosis and non-ATTs. We reviewed the data regarding poor MA to ATT in PAD patients.

Design: Systematic review

Method: Our protocol was based on the PRISMA statement. PubMed, EMBASE, and Cochrane Library were searched from inception to June 2023. Publications with a (sub)cohort of PAD patients that reported on patients' MA to ATT were included. The main exclusion criteria were reviews, expert opinions, and, case reports. All articles were reviewed on eligibility and methodological quality by 2 independent researchers. Primary objective was the proportion of patients with poor MA following patient-, pharmacy- or laboratory-reported outcome measurements. Poor MA is a combined endpoint of primary nonadherence (inability to initiate a prescription), secondary nonadherence (incorrect daily intake), and nonpersistence (discontinuation of daily intake).

Results: We identified 274 potentially relevant records of which 10 studies (32,628 patients) were included. Six studies were RCTs, 2 prospective-, and 2 retrospective studies. Most studies scored a moderate risk of bias and had heterogeneous study designs. Poor MA rates ranged between 2-45%. Higher rates of poor MA were found

Enseignement Superieur (ABES) Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies

BMJ Open

in studies with longer follow-ups, pharmacy-reported outcome measurements, and registry-based cohorts.

Conclusion: Heterogeneous study designs create a wide dispersion in the proportions. However, poor MA to ATT was found in approximately one-third of the PAD patients and seemed to increase with longer therapy duration which highlights the magnitude of this societal challenge.

Funding: This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.

PROSPERO registration number: CRD42023431803

INTRODUCTION

Peripheral arterial disease (PAD) is associated with a high risk of atherothrombotic events (AE).(1, 2) The annual cardiovascular mortality risk of patients with intermittent claudication is approximately 5% compared to 11.5% for patients with critical limb-threatening ischemia.(3) In contrast to other atherosclerotic diseases such as coronary artery disease and cerebrovascular diseases, the overall long-term risk of major adverse cardiovascular events (MACE) of PAD patients is 2-fold worse.(4, 5) Last decades, revascularisation techniques have improved which resulted in a 40% reduction in major lower limb amputations. However, the high cardiovascular mortality risk has barely declined.(1, 2, 6, 7)

A cornerstone in PAD management is prevention of MACE through pharmacological therapies through lifelong antihypertensives, statins, and antithrombotic therapy (ATT).(1, 2, 8) Medication adherence (MA), which is the ability to take medication following prescriptions, is believed to be an essential factor for pharmacological therapies to be effective.(9, 10) However, approximately 50% of patients with long-term medication due to chronic diseases in developed countries have a poor MA.(11) More specifically, in patients with cardiovascular protective medicines, poor MA was found in 25-80%.(12-15) Nevertheless, the majority of these studies are outdated and primarily concentrate on patients without PAD diagnosis and non-ATTs. MA is partly influenced by overarching factors such as healthcare systems, but many factors are disease- and patient-related such as clinical symptoms, socioeconomic background, and, medication side effects.(15-17) This underscores the importance of reporting on MA rates in specific patient populations and medication groups.

MA comprises two main elements: 'adherence' (or 'compliance') and 'persistence'.(9, 15). No universally accepted consensus exists, however, adherence is mainly used to describe correct daily intake and persistence represents the continuation of daily intake.(9, 15) Adherence can be subdivided into primary- (or initiation) and secondary adherence to differentiate between the ability to initiate a new prescription and the daily intake after initiating the first prescription. Patients are mostly considered adherent when approximately 80% of the intake is as prescribed.(18, 19) MA is measured through patient- (questionnaires), pharmacy- (counting pills, refill records), or biochemical/laboratory-reported outcome measurements (Table S1).(20)

The optimal ATT in PAD patients is still under debate.(1, 8, 21, 22) MA is generally not discussed in trials although poor MA might lead to substantial bias and thus erroneous outcomes. As far as we are aware, there are no systematic analyses regarding MA to ATT prescriptions in PAD patients. Therefore, we initiated this study to assess medication adherence specifically for ATT in patients with PAD.

METHODS

 The protocol of this systematic review was based on the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA)-statement (PROSPERO: CRD42023431803).(23, 24)

Search strategy and study selection

The systematic literature search was performed from inception to June 7th, 2023. The bibliographic databases PubMed, Embase.com, and Wiley/Cochrane Library were used. The index terms "Peripheral Arterial Disease", "Antithrombotic Drugs", "Treatment Adherence and Compliance" along with their synonyms and/or closely related words, were included. The search was compiled by a medical database specialist (see Figures S1, S2, and S3).

The search results were first deduplicated to which all obtained articles were screened on title and abstract by two independent researchers (EW and BM). Subsequently, the remaining articles were fully reviewed for eligibility and the references were screened for relevant publications (Figure S4). In case of disagreement, the study was reviewed by a third reviewer (CU).

Eligible publications contained a (sub)population of adult PAD patients and reported on patients' (non)adherence and/or (non)persistence to ATT. Publications before the year 2000, review articles, expert opinions, case reports, use of polypills, only nurse-led intensified follow-up, and non-English articles were excluded (Figure S4).

Outcome definitions and measurements

The primary objective was the proportion of PAD patients with poor MA following patient-, pharmacy-, or biochemical/laboratory-reported outcome measurements (Table S1). Poor MA includes; primary nonadherence (the inability to initiate a new prescription), secondary nonadherence (incorrect daily dosage/timing/frequency after initiating a new prescription), and nonpersistence (discontinuation of the medication intake).(9, 15, 20)

Secondary objectives were the proportion of PAD patients with (1) poor MA following pharmacy-reported outcome measurements, (2) primary nonadherence following pharmacy-reported- and (3) all outcome measurements, (4) secondary (short- and long-term) nonadherence following pharmacy-reported- and (5) all outcome measurements, and (6) nonpersistence following pharmacy-reported- and (7) all outcome measurements. Short-term was defined as a maximum follow-up of 6 months and long-term follow-up was defined as more than 6 months.

Data extraction and data analysis

The extracted data included; first author, year of publication, study design, country, number of PAD subjects, disease stage, mean age, male-female ratio, type of ATT, type of MA subgroup(s), the proportions of the MA, follow-up length, the MA outcome measurement.

The data were retrieved and collected in Review Manager Web (RevMan Web), version 4.14.0., The Cochrane Collaboration, Londen, UK. The number of patients who were adherent/persistent and nonadherent/nonpersistent were extracted from the articles. Subsequently, the proportions of adherence/persistence and nonadherence/nonpersistence were calculated and processed in tables. Clinical homogeneity was assessed based on the study designs and definitions of nonadherence and/or non-persistence.

Quality assessment

The Cochrane Risk-of-Bias (ROB) tool was applied to assess the quality of the included randomised controlled trials (RCTs) that reported MA as primary outcome. The Cochrane ROB tool identifies different domains of bias and classifies risk into high-, low-, or unclear risk.(25) The overall quality was deemed high if all domains had a low ROB or 1 domain was unclear. Unclear ROB was considered if $2 \ge$ domains were unclear and high ROB was assigned if $1 \ge$ domain had a high ROB.

For the non-RCTs and RCTs that report MA as a subanalysis, the methodological index for non-randomised studies (MINORS) score was used.(26) This method provides a 12-item list for comparative studies and an 8-item list for noncomparative studies. This score contains 3 classes; 0 (not reported), 1 (reported inadequate), and 2 (reported adequate). The overall quality for non-comparative trials was considered poor if the score was ≤ 8 , moderate between 9-14, and good if ≥ 15 . For the comparative trials, the score ranges were ≤ 15 , 16-22, and ≥ 23 .

RESULTS

Screening process

The search identified 274 potentially relevant records after deduplicating. No articles were added by cross-linking. After reviewing the title and abstract, 227 articles were excluded and 4 articles could not be retrieved. The remaining 45 records were fully screened of which 10 records could be included; 6 RCTs, 2 prospective-, and 2 retrospective studies (Figure S1). In case of conflicting screening decisions, consensus was found between EW and BM.

Risk-of-bias assessment

Enseignement Superieur (ABES) Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

Three articles were RCTs with MA as the main analysis of the trial and, therefore, the Cochrane ROB tool was used (Table S2). The MINOR-score was used for the other 7 articles (Table S3). Overall, most studies had a moderate ROB. Concerns regarding the ROB arise mostly due to patient-reported outcomes and non-adjudicated endpoints that could be easily influenced by knowledge of the intervention. Moreover, most articles did not calculate a sample size based on the MA outcome.

Study sample/study characteristics

The characteristics of the included studies are shown in Table 1. In total 32628 PAD patients were analysed. Most studies were executed in Europe, however, the two largest trials (EUCLID and VOYAGER PAD) that accounted for 63% of the included patients were executed in various countries and continents.(27, 28) MA was mostly reported as a sub-analysis. The included trials had rather heterogeneous study designs, making a meta-analysis infeasible.

	1	1			1	1	1	1	1
	1st	Country	YOP	PAD	Severity	ATT	Age	Female	FU (M)
	Author			cohort	disease			(%)	
Ran	domised cont	trolled trials							
1	Cassar (42)	United	2006	67	R1-3 w	A w C or	Mn 66	15 (22)	1
		Kingdom			EVR	PLB	(R: 43-80)		
2	Haile (30)	Sweden	2022	105	R1-3 w	Any ATT	Md 72	54 (52)	12
					EVR/SVR		(IQR: 69-77)		
3	Hess (28)	Multiple	2022	6564	R1-6 w	ASA w PLB	Mn 68	1704 (26)	Md 28 (IQR:
					EVR/SVR 🔍	or DOAC	(IQR: 60-76)		22-34)
4	Jivegard	Sweden	2005	281	R4-6	ASA w PLB	Mn 74	126 (45)	3
	(46)					or LMWH	(SD:9)		
5	Qvist (29)	Denmark	2019	2051	R 0-6 w/o	Any ATT	Mn 70	0 (0)	60
					EVR/SVR		(SD: 2.9)		
6	Weissler	Multiple	2022	13842	R1-6 w/o	C or T	Mn 67	3884 (28)	30 (up to 42)
	(27)				EVR/SVR		(IQR: 59-75)		
Pros	spective trials	5				·			
7	Ferreira	Spain	2010	194	NR	Any APT	Mn 64	43 (22)	12
	(43)						(SD: 11.2)		
8	Kremers	Netherlands	2023	246	R1-4	Any APT	Mn 69	105 (43)	12
	(47)						(SD: 9.2)		
Retr	rospective stu	ıdies							
9	Halle (32)	United	2017	100	R1-6 w/o	Any APT	Mn 64	42 (42)	NR
		States			EVR/SVR		(SD: 9.5)		
10	Wawruch	Slovak	2021	9178	R 0-6 w/o	Any APT	Mn 75	5285 (58)	60
	(31)	Republic			EVR/SVR				
Tota	al			32628				11258 (35)	

YOP = year of publication; w = with; w/o = with or without; A = acetylsalicylic acid; ATT = antithrombotic therapy; DOAC = direct-acting oral anticoagulant; PLB = placebo; LMWH = low molecule weight heparin; C = clopidogrel; APT = antiplatelet therapy; NR = not reported; EVR = endovascular revascularisation; SVR = surgical/open revascularisation; Mn = mean; Md = median; R = range; SD=standard deviation; M = Months.

Table 1: Articles eligible for this systematic review

Medication adherence

Poor MA following all outcome measurements ranged between 2-45% and following pharmacy-reported measurements between 9-45% (Table 2). One study, however, reported on all 3 subcategories of poor MA (i.e. primary-, secondary adherence, and persistence) and reported a total risk of 33%.(29) Overall, higher proportions of poor MA were found in studies with longer follow-ups, pharmacy-reported outcomes, and registry-based methods.(29-31)

One study reported on primary nonadherence and was based on a pharmacyreported outcome measurement which occurred in 31% of the study population (Table 3). Short-term secondary nonadherence was reported in 3 articles and ranged between 9-26% (Table 4). Two of the 3 articles applied pharmacy-reported outcome measurement and found rates between 9-21%. Long-term secondary nonadherence, described in 5 articles, showed rates ranging between 5-26% which are comparable rates to the short-term secondary nonadherence (Table 4). Following the pharmacyreported outcome measurement long-term secondary nonadherence occurred in 14-20% of the patients. Lastly, nonpersistence was found between 2-33% (Table 5). Nonpersistence within the pharmacy-reported group ranged between 27-33%. Higher rates of nonpersistence were found in studies with longer follow-ups and registrybased methods.

Nr.	Ref.	Measurement (Table S1)	Good MA	Poor MA	FU period (M)
Phar	macy ROM				
1	Cassar (42)	В	91%	9%	6
2	Haile (30)	B, C	70%	30%	18
3	Qvist (29)	С	55%	45%*	60
4	Wawruch (31)	С	57%	43%	60
Phar	macy- and patier	nt-ROM	•		•
5	Hess (28)	Patient-reported (NR) and	68%	8%	Md 28 (IQR: 22-
		pharmacy-reported (B)			34)
Patie	ent-ROM				
6	Ferreira (43)	NVQ	82%	2%	12
7	Halle (32)	G	74%	26%	NR
8	Jivegard (46)	NVQ	74%	26%	3
9	Kremers (47)	D	95%	5%	12
10	Weissler (27)	NR	72%	10%	30 (up to 42)

MA = medication adherence; NVQ = non-validated questionnaire; NR = not reported; Md = median; M = months; IQR = interquartile range; ROM = reported outcome measurements

* Nonpersistence is excluded since the proportion of the patient who were nonadherent and nonpersistent is lacking. *Table 2: Medication adherence*

Nr	Ref.	Measurement (Table S1)	Adherence	Nonadherence	FU period (M)
Pharr	nacy-ROM				

Enseignement Superieur (ABES) Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

1 Qvist (29) C 69% 31% 60						
	1	Qvist (29)	С	69%	31%	60

ROM = reported outcome measurements

Table 3: Primary nonadherence

Nr.	Ref.	Measurement (Table S1)	Adherence	Nonadherence	FU period (M)					
	Short-term secondary nonadherence									
Phari	macy-ROM									
1	Cassar (42)	В	91%	9%	6					
2	Haile (30)	B, C	79%	21%	6					
Patie	nt-ROM									
3	Jivegard (46)	NVQ	74%	26%	3					
	Long-term secondary nonadherence									
Phari	macy-ROM									
1	Haile (30)	B, C	86%	14%	18					
2	Qvist (29)	С	80%	20%	60					
3	Wawruch (31)	С	80%	20%	60					
Patie	Patient-ROM									
4	Halle (32)	G	74%	26%	NR					
5	Kremers (47)	D	95%	5%	12					

NVQ = non-validated questionnaire; ROM = reported outcome measurements

Table 4: Secondary nonadherence

Nr.	Ref.	Measurement (Table 1)	Persistence	Nonpersistence*	FU period (M)
Phari	macy-ROM				
1	Qvist (29)	С	73%	27%	60
2	Wawruch (31)	С	67%	33%	60
Phari	macy- and patient	-ROM			
3	Hess (28)	Patient-reported (NR) and	68%	8%	Md 28 (IQR:
		pharmacy-reported (B)			22-34)
Patie	nt-ROM				
4	Ferreira (43)	NVQ	82%	2%	12
5	Weissler (27)	NR	72%	10%	30 (up to 42)

• * Non-persistent due to patients' decisions. The proportion of persistence and nonpersistence might not be 100% due to other trial-related reasons such as major bleeding.

 NVQ = non-validated questionnaire; NR = not reported; Md = median; M = months; IQR = interquartile range; ROM = reported outcome measurements

Table 5: Nonpersistence

DISCUSSION

This systematic review provides an overview of the literature about MA to ATT in patients with PAD. The results demonstrate a poor MA rate of approximately one-third. Despite the dispersion of poor MA rates, it shows an insight into the extent of the issue. Higher rates of poor MA were found in studies with longer follow-ups, pharmacy-reported outcomes, and registry-based methods. The secondary objectives show that all subcategories seem to have a nearly equal share in the overall risk of nonadherence.

The trial designs, such as the study type and length of follow-up, might explain partly the dispersion in MA. In this review, 3 articles required minimum effort from participants because of the registry-based or retrospective design and the other articles included extensive follow-up, additional injections, and/or blood samples. Designs that required minimum effort, showed the highest rate of poor MA, nonadherence, and/or nonpersistence.(29, 31, 32) It is plausible that the likelihood of creating a more representative sample rises as the required effort for patients decreases. Literature shows that PAD patients are more precarious compared to patients with other chronic diseases including other atherosclerotic diseases.(33, 34) Precariousness is related to a lower socioeconomic status and patients with low socioeconomic status are less likely to participate in trials.(12, 33, 35, 36)

Regarding the length of follow-up, the literature shows trends that poor MA increases over time.(37-39) This review shows similar results (Tables 2, 4, and 5). One study showed that the highest proportion of nonadherence predominantly occurred between 13 and 24 months with 44% and 35.5% respectively compared to 17% within the first 12 months. This pattern corresponds with the dispersion in our long-term nonadherence results (Table 4).(31)

Additionally, the heterogeneity of the reporting methods, such as the definition of MA and outcome measurements, might be contributing to the variety in proportions between studies. MA includes 3 subcategories; primary nonadherence, secondary nonadherence, and nonpersistence. Most articles, except one, researched only nonpersistence and/or secondary nonadherence. This might underestimate the proportion of poor MA by not identifying all categories of MA. The study that distinguished all 3 subcategories reported the highest proportion of poor MA.(29)

The included studies used patient- or pharmacy-reported measurements to identify poor MA. Patient-reported outcome measurements, i.e. questionnaires and interviews, are at risk for multiple biases such as recall bias compared to pharmacy-reported outcome measurements, i.e. counting returned pills or refill patterns which lead to potentially misleading low rates of poor MA.(13, 40) One study compared patient- with pharmacy reported outcomes and their results confirm this hypothesis.(30) However, our results do not fully confirm this.

Healthcare systems have a major influence on MA.(15-17, 35) One study showed that subjects from North America were more likely to discontinue their medication compared to subjects from Europe.(27) Another study executed in North America confirmed that the inability to afford medication was a major reason for poor MA.(32) Most European countries have similar healthcare systems that reimburse necessary health costs.(41)

Regarding patient-related factors, studies that include post-revascularized PAD patients might show slightly higher MA rates.(28, 30, 42) One study showed lower long-term secondary nonadherence compared to short-term nonadherence.(30) These patients underwent revascularisation at 6 months follow-up. The severity of the symptoms might affect patients' perception of treatments. However, the literature is ambiguous.(32) Equivocal evidence regarding the impact of patient-related factors on MA is common. Amongst the included studies, subanalyses of patient-related factors show heterogeneous results.(27, 28, 31, 32, 43)

To estimate the individual risk of poor MA, it is of interest whether nonadherence leads to nonpersistence. It seems that adherent and nonadherence patients are both highly at risk for nonpersistence and thus poor MA.(31) The reason given is the lack of awareness regarding the life-long indication for ATT in PAD patients. We advise physicians to discuss MA with PAD patients. Additional research on all subcategories of MA based on registries that use pharmacy refill records and have extensive follow-up are warranted to confirm our findings.

CONCLUSION

Studies regarding MA to ATT in PAD patients are scarce and heterogeneous designs create a wide dispersion in the proportions. However, poor MA to ATT was found in approximately one-third of the PAD patients and seemed to increase with longer duration of ATT use, which highlights the magnitude of this societal challenge.

AUTHOR CONTRIBUTIONS:

EW: Concept and design, screening, data collection, analyses and interpretation of data, writing of manuscript, final approval.

BM: Screening, data collection and analyses, final approval.

CU: Concept and design, revision of manuscript, final approval.

GJdB: Concept and design, revision of manuscript, final approval.

DATA STATEMENT:

Access to the data is available via the correspondence of this article.

REFERENCES

1. Aboyans V, Ricco JB, Bartelink MEL, Björck M, Brodmann M, Cohnert T, et al. Editor's Choice -2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS). Eur J Vasc Endovasc Surg. 2018;55(3):305-68.

2. Twine CP, Kakkos SK, Aboyans V, Baumgartner I, Behrendt CA, Bellmunt-Montoya S, et al. Editor's Choice - European Society for Vascular Surgery (ESVS) 2023 Clinical Practice Guidelines on Antithrombotic Therapy for Vascular Diseases. Eur J Vasc Endovasc Surg. 2023;65(5):627-89.

3. van Haelst STW, Koopman C, den Ruijter HM, Moll FL, Visseren FL, Vaartjes I, et al. Cardiovascular and all-cause mortality in patients with intermittent claudication and critical limb ischaemia. Br J Surg. 2018;105(3):252-61.

4. Welten GM, Schouten O, Hoeks SE, Chonchol M, Vidakovic R, van Domburg RT, et al. Longterm prognosis of patients with peripheral arterial disease: a comparison in patients with coronary artery disease. J Am Coll Cardiol. 2008;51(16):1588-96.

5. Steg PG, Bhatt DL, Wilson PW, D'Agostino R, Sr., Ohman EM, Röther J, et al. One-year cardiovascular event rates in outpatients with atherothrombosis. Jama. 2007;297(11):1197-206.

6. Barnes JA, Eid MA, Creager MA, Goodney PP. Epidemiology and Risk of Amputation in Patients With Diabetes Mellitus and Peripheral Artery Disease. Arterioscler Thromb Vasc Biol. 2020;40(8):1808-17.

7. Voci D, Fedeli U, Valerio L, Schievano E, Righini M, Kucher N, et al. Mortality rate related to peripheral arterial disease: A retrospective analysis of epidemiological data (years 2008-2019). Nutr Metab Cardiovasc Dis. 2023;33(3):516-22.

8. Conte MS, Pomposelli FB, Clair DG, Geraghty PJ, McKinsey JF, Mills JL, et al. Society for Vascular Surgery practice guidelines for atherosclerotic occlusive disease of the lower extremities: management of asymptomatic disease and claudication. J Vasc Surg. 2015;61(3 Suppl):2s-41s.

9. Cramer JA, Roy A, Burrell A, Fairchild CJ, Fuldeore MJ, Ollendorf DA, et al. Medication compliance and persistence: terminology and definitions. Value Health. 2008;11(1):44-7.

10. Simpson SH, Eurich DT, Majumdar SR, Padwal RS, Tsuyuki RT, Varney J, et al. A meta-analysis of the association between adherence to drug therapy and mortality. Bmj. 2006;333(7557):15.

Sabaté E. Adherence to long-term therapies: evidence for action: World Health Organization;
 2003.

12. Baroletti S, Dell'Orfano H. Medication adherence in cardiovascular disease. Circulation. 2010;121(12):1455-8.

13. Naderi SH, Bestwick JP, Wald DS. Adherence to drugs that prevent cardiovascular disease: meta-analysis on 376,162 patients. Am J Med. 2012;125(9):882-7.e1.

14. Memon RA, Raveena Bai B, Simran F, Kumari M, Aisha F, Sai Kiran K, et al. Effect of the Polypill on Adherence and Prevention of Cardiovascular Diseases in Patients With or at High Risk of Cardiovascular Diseases: A Meta-Analysis of Randomized Controlled Trials. Cureus. 2023;15(1):e34134.

15. Ho PM, Bryson CL, Rumsfeld JS. Medication adherence: its importance in cardiovascular outcomes. Circulation. 2009;119(23):3028-35.

16. Kardas P, Lewek P, Matyjaszczyk M. Determinants of patient adherence: a review of systematic reviews. Front Pharmacol. 2013;4:91.

17. Osterberg L, Blaschke T. Adherence to medication. N Engl J Med. 2005;353(5):487-97.

18. Svarstad BL, Chewning BA, Sleath BL, Claesson C. The Brief Medication Questionnaire: a tool for screening patient adherence and barriers to adherence. Patient Educ Couns. 1999;37(2):113-24.

19. Karve S, Cleves MA, Helm M, Hudson TJ, West DS, Martin BC. Good and poor adherence: optimal cut-point for adherence measures using administrative claims data. Curr Med Res Opin. 2009;25(9):2303-10.

20. Lam WY, Fresco P. Medication Adherence Measures: An Overview. Biomed Res Int. 2015;2015:217047.

21. Gerhard-Herman MD, Gornik HL, Barrett C, Barshes NR, Corriere MA, Drachman DE, et al. 2016 AHA/ACC Guideline on the Management of Patients with Lower Extremity Peripheral Artery Disease: Executive Summary. Vasc Med. 2017;22(3):Np1-np43.

22. Willems LH, Maas D, Kramers K, Reijnen M, Riksen NP, Ten Cate H, et al. Antithrombotic Therapy for Symptomatic Peripheral Arterial Disease: A Systematic Review and Network Meta-Analysis. Drugs. 2022;82(12):1287-302.

23. Page MJ, Moher D, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. PRISMA 2020 explanation and elaboration: updated guidance and exemplars for reporting systematic reviews. Bmj. 2021;372:n160.

24. Rethlefsen ML, Kirtley S, Waffenschmidt S, Ayala AP, Moher D, Page MJ, et al. PRISMA-S: an extension to the PRISMA Statement for Reporting Literature Searches in Systematic Reviews. Syst Rev. 2021;10(1):39.

25. Higgins JP, Altman DG, Gøtzsche PC, Jüni P, Moher D, Oxman AD, et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. Bmj. 2011;343:d5928.

26. Slim K, Nini E, Forestier D, Kwiatkowski F, Panis Y, Chipponi J. Methodological index for nonrandomized studies (minors): development and validation of a new instrument. ANZ J Surg. 2003;73(9):712-6.

27. Weissler EH, Mulder H, Rockhold FW, Baumgartner I, Norgren L, Blomster J, et al. Understanding Study Drug Discontinuation Through EUCLID. Frontiers in Cardiovascular Medicine. 2022;9.

28. Hess CN, Baumgartner I, An, SS, Nehler MR, Patel MR, et al. Sex-Based Differences in Outcomes Following Peripheral Artery Revascularization: Insights From VOYAGER PAD. J Am Heart Assoc. 2022;11(12):e024655.

29. Qvist I, Søgaard R, Lindholt JS, Lorentzen V, Hallas J, Frost L. Adherence to Prescribed Drugs Among 65-74 Year Old Men Diagnosed with Abdominal Aortic Aneurysm or Peripheral Arterial Disease in a Screening Trial: A VIVA Substudy. Eur J Vasc Endovasc Surg. 2019;57(3):442-50.

30. Haile ST, Joelsson-Alm E, Johansson UB, Lööf H, Palmer-Kazen U, Gillgren P, et al. Effects of a person-centred, nurse-led follow-up programme on adherence to prescribed medication among patients surgically treated for intermittent claudication: randomized clinical trial. Br J Surg. 2022;109(9):846-56.

31. Wawruch M, Murin J, Tesar T, Paduchova M, Petrova M, Celovska D, et al. Adherence to Antiplatelet Medications among Persistent and Non-Persistent Older Patients with Peripheral Arterial Disease. Biomedicines. 2021;9(12).

32. Halle TR, Benarroch-Gampel J, Teodorescu VJ, Rajani RR. Surgical Intervention for Peripheral Artery Disease Does Not Improve Patient Compliance with Recommended Medical Therapy. Ann Vasc Surg. 2018;46:104-11.

33. Joly M, Gillois P, Satger B, Blaise S, Pernod G. Comparative evaluation of socioeconomic insecurity in peripheral and coronary artery disease patients. J Med Vasc. 2022;47(5-6):220-7.

34. Chang P, Nead KT, Olin JW, Cooke JP, Leeper NJ. Clinical and socioeconomic factors associated with unrecognized peripheral artery disease. Vasc Med. 2014;19(4):289-96.

35. De Geest S, Sabaté E. Adherence to long-term therapies: evidence for action. Eur J Cardiovasc Nurs. 2003;2(4):323.

36. Ohm J, Jernberg T, Johansson D, Warnqvist A, Leosdottir M, Hambraeus K, et al. Association of clinical trial participation after myocardial infarction with socioeconomic status, clinical characteristics, and outcomes. Eur Heart J Open. 2021;1(2):oeab020.

BMJ Open

 37. Krousel-Wood M, Joyce C, Holt E, Muntner P, Webber LS, Morisky DE, et al. Predictors of decline in medication adherence: results from the cohort study of medication adherence among older adults. Hypertension. 2011;58(5):804-10.

38. Newby LK, LaPointe NM, Chen AY, Kramer JM, Hammill BG, DeLong ER, et al. Long-term adherence to evidence-based secondary prevention therapies in coronary artery disease. Circulation. 2006;113(2):203-12.

39. Jackevicius CA, Mamdani M, Tu JV. Adherence with statin therapy in elderly patients with and without acute coronary syndromes. Jama. 2002;288(4):462-7.

40. Zini MLL, Banfi G. A Narrative Literature Review of Bias in Collecting Patient Reported Outcomes Measures (PROMs). Int J Environ Res Public Health. 2021;18(23).

41. Davis K, Stremikis K, Squires D, Schoen C. Mirror, mirror on the wall. How the performance of the US Health care system compares internationally New York: CommonWealth Fund. 2014.

42. Cassar K, Bachoo P, Ford I, Greaves M, Brittenden J. Variability in Responsiveness to Clopidogrel in Patients with Intermittent Claudication. European journal of vascular and endovascular surgery. 2006;32(1):71-5.

43. Ferreira-González I, Marsal JR, Ribera A, Permanyer-Miralda G, García-Del Blanco B, Martí G, et al. Background, incidence, and predictors of antiplatelet therapy discontinuation during the first year after drug-eluting stent implantation. Circulation. 2010;122(10):1017-25.

44. Morisky DE, Ang A, Krousel-Wood M, Ward HJ. Predictive validity of a medication adherence measure in an outpatient setting. J Clin Hypertens (Greenwich). 2008;10(5):348-54.

45. Knobel H, Alonso J, Casado JL, Collazos J, González J, Ruiz I, et al. Validation of a simplified medication adherence questionnaire in a large cohort of HIV-infected patients: the GEEMA Study. Aids. 2002;16(4):605-13.

46. Jivegård L, Drott C, Gelin J, Groth O, Hensäter M, Jensen N, et al. Effects of three months of low molecular weight heparin (dalteparin) treatment after bypass surgery for lower limb ischemia--a randomised placebo-controlled double blind multicentre trial. European journal of vascular and endovascular surgery. 2005;29(2):190-8.

47. Kremers BMM, Daemen JHC, Ten Cate H, Spronk HMH, Mees BME, Ten Cate-Hoek AJ. Inadequate response to antiplatelet therapy in patients with peripheral artery disease: a prospective cohort study. Thromb J. 2023;21(1):5. Enseignement Superieur (ABES) Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies

Enseignement Superieur (ABES) Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

SUPPLEMENTARY FILE

Tables

Outcome	Nr*	Specification examples [description]
measurements		
pharmacist-reported	А	Medication Event Monitoring System (MEMS) [Use of electronic devices with
outcome		microchips to record medication intake]
measurements	В	Pharmacy records [Counting returned pills and tracking refill patterns]
	С	Prescription records registers [Tracking all dispensed drugs and tracking refill patterns]
Patient-reported	D	Morisky Medication Adherence Scale (MMAS-8)(44)
outcome	E	Medication Adherence Report Scale (MARS)(12)
measurements	F	Simplified Medication Adherence Questionnaire (SMAQ)(45)
	G	Brief Medication Questionnaire (BMQ)(18)
	Н	Other
Biochemical or	Ι	INR, Platelet activity
laboratory outcome		
measurements		

* This table does not include all existing measurements.

Table S1: Outcome measurements



ROB = risk of bias; x = high risk of Bias; ? = unclear risk of Bias; v = low risk of bias

Table S2. Risk-of-bias summary of included RCTs following the Cochrane risk-of-bias tool



For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

Ferreira, 2010 (43)	2	0	2	2	0	2	0	0	N/A	N/A	N/A	N/A	8/16	Р
Halle, 2017 (32)	2	2	2	2	1	1	2	0	N/A	N/A	N/A	N/A	12/1 6	M
Hess, 2022 (28)	1	1	2	1	1	2	2	0	N/A	N/A	N/A	N/A	10/1 6	М
Kremers, 2023 (47)	2	1	2	2	1	2	2	0	N/A	N/A	N/A	N/A	12/1 6	М
Qvist, 2019 (29)	2	1	1	2	2	2	2	0	N/A	N/A	N/A	N/A	12/1 6	М
Wawruch, 2021 (31)	2	2	1	2	2	2	2	0	N/A	N/A	N/A	N/A	13/1 6	М

N/A = not applicable; P = Poor; M = Moderate; G = good

Table 53. Risk-of-bias of bias summary for the non-randomised controlled trials following the MINORs-score

Enseignement Superieur (ABES) Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

Figures

Search	Actions	Details	Query	Results	Time
#4		0>	Search: #1 AND #2 AND #3 Sort by: Most Recent	128	0 <mark>8:5</mark> 0:30
#3		0 >	Search: "Treatment Adherence and Compliance"[Mesh] OR "Medication Adherence"[Mesh]] OR "compliance" [tiab] OR "adherence" [tiab] OR "refus*"[tiab] OR "nonadherence"[tiab] OR "noncompliance"[tiab] Sort by: Most Recent	542,177	08:50:03
#2		•	Search: "Platelet Aggregation Inhibitors" [Mesh] OR "Platelet Aggregation Inhibitors" [Pharmacological Action] OR "Dual Anti- Platelet Therapy" [Mesh] OR "Platelet aggregation inhibitor*" [tiab] OR "antiplatelet therap*" [tiab] OR "anti platelet therap*" [tiab] OR OR "platelet inhibitor*" [tiab] OR "platelet aggregant*" [tiab] OR "acetylsalicylic acid" [tiab] OR "platelet aggregant*" [tiab] OR "acetylsalicylic acid" [tiab] OR "Anticoagulants" [Mesh] OR "Anticoagulants" [Pharmacological Action] OR "Indirect thrombin inhibitor*" [tiab] OR "anti coagulant" [tiab] OR "Fibrinolytic Agents" [Mesh] OR "fibrinolytic agent*" [tiab] OR "fibrinolytic drug*" [tiab] OR "Thrombolytic drug*" [tiab] OR "Anticombolytic agent*" [tiab] OR "antithrombotic drug*" [tiab] OR "Thrombolytic agent*" [tiab] OR "antithrombotic drug*" [tiab] OR "Factor Xa inhibitor*" [tiab] OR "Rivaroxaban" [tiab] Sort by: Most Recent	468,945	08:49:49
#1		>	Search: ("Peripheral Arterial Disease" [Mesh] OR "peripheral arterial disease*" [tiab] OR "peripheral artery disease*" [tiab] OR "lower extremity arterial disease*" [tiab] OR "lower extremity artery disease*" [tiab] OR "Chronic Limb-Threatening Ischemia*" [tiab] OR "intermittent claudication*" [tiab] OR "Peripheral Arterial Vascular Disease*" [tiab] OR "peripheral artery occlusive disease*" [tiab] OR "peripheral arterial occlusive disease*" [tiab]) AND ("Peripheral Arterial Disease" [Mesh] OR "peripheral arterial disease*" [tiab] OR "peripheral artery disease*" [tiab] OR "lower extremity arterial disease*" [tiab] OR "lower extremity artery disease*" [tiab] OR "Chronic Limb-Threatening Ischemia*" [tiab] OR "intermittent claudication*" [tiab] OR "Peripheral Arterial Vascular Disease*" [tiab] OR "peripheral artery occlusive disease*" [tiab] OR "Chronic Limb-Threatening Ischemia*" [tiab] OR "peripheral arterial occlusive disease*" [tiab] OS "bort by: Most Recent	32,848	08:44:08











Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

Figure S4. The flowchart of the selection process

BMJ Open

BMJ Open

Medication adherence of patients with peripheral arterial disease to antithrombotic therapy: a systematic review

1	DMI On an
Journal:	вму Ореп
Manuscript ID	bmjopen-2024-085056.R1
Article Type:	Original research
Date Submitted by the Author:	16-Jul-2024
Complete List of Authors:	Wegerif, Emilien; University Medical Centre Utrecht, Vascular surgery Mol, Barend; University Medical Centre Utrecht, Department of Vascular Surgery Ünlü, Çağdaş; Noordwest Ziekenhuisgroep, Vascular surgery de Borst, Gert-Jan; University Medical Centre Utrecht, Vascular Surgery
Primary Subject Heading :	Surgery
Secondary Subject Heading:	Cardiovascular medicine, Patient-centred medicine
Keywords:	Medication Adherence, Medication Persistence < Medication Adherence, Medication Review, Systematic Review, Vascular surgery < SURGERY, VASCULAR MEDICINE





I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our <u>licence</u>.

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which <u>Creative Commons</u> licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

terez oni

Enseignement Superieur (ABES) Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies



2			
3 4	1	Medication ad	herence of patients with peripheral arterial
5	2	disease to anti	thrombotic therapy: a systematic review
7	3		
8	4	Emilien C. J. Wegerif.	MD. MSc ^{1A} . Barend Mol. MD ^{2A} . Caŭdas Ünlü. MD. Ph.D ^{3B} . Gert J. de
9 10	5	Borst MD Ph D ^{4A}	
11	6	<u>Bolot, MB, M.B.</u>	
12	7	Affiliations	
13 14	, 8	A University Me	dical Center Utrecht, Department of Vascular Surgery, Circulatory
15	q	Health Heide	berglaan 100, 3584CX, Utrecht, the Netherlands
16 17	10	B NoordWest 7	ekenhuisgroen, Denartment of Vascular Surgery, Wilhelminalaan 12
18	10		exeminasyloep, Department of Vascular Surgery, Wilhelminalaan 12,
19	12	1013 JD, AIKII	
20 21	12	Konworde: Madicatic	an Adherence, Treatment Adherence and Compliance, Peripheral Arterial
22	10	Disease Distalet Age	regation Inhibitors, Anticoagulants, Systematic Daview
23	14	Disease, Platelet Agg	regation inhibitors, Anticoaguiants, Systematic Review.
24 25	15	Conflict of interests	Name of the outhous have any conflicts of interact reproveding this outide
26	10	Conflict of Interest:	None of the authors have any connicts of interest regarding this article.
27 29	17	• • • • • • • • • • • • • • • • • • •	ah ha a ha an ang anta dha tha thair anit . Ma diaal Cantan Utara ba
29	18	Location: This resear	ch has been executed at the University Medical Center Otrecht.
30	19		
31 32	20	Funding: This researc	ch received no specific grant from any funding agency in the public,
33	21	commercial, or not-fo	pr-profit sectors.
34 25	22		
35 36	23	Competing interest:	There is no competing interest.
37	24		
38 30	25	Correspondence:	
40	26	E.C.J. Wegerif, MD, M	Sc, PhD candidate, University Medical Center Utrecht, Department of
41	27	Vascular Surgery, Circ	culatory Health, Heidelberglaan 100, 3584CX, Utrecht, the Netherlands
42 43	28	Phone number:	+31 887556965
44	29	Email:	e.c.j.wegerif@umcutrecht.nl
45 46	30		
40 47	31	Word count:	Abstract: 300 Body: 2100
48	32		
49 50	33		
51			
52			
53 54			
55			
56 57			
58			
59			
60			
			1

Strengths and limitations of this study This review is based on the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA)-statement and contains a comprehensive search compiled by a medical database specialist. • Studies regarding medication adherence of patients with peripheral arterial disease to antithrombotic therapy are scarce, leading to limited data. • The included trials had rather heterogeneous study designs, making a meta-analysis infeasible and creating a wide dispersion in medication adherence proportions. This review provides insight into the extent of the patient's poor medication adherence which is an addition to the current literature focussing primarily on physician adherence. ABSTRACT Introduction: Patients with peripheral arterial disease (PAD) have a high risk of atherothrombotic events (AE). Antithrombotic therapy (ATT) is an important component in the treatment armamentarium to prevent AE. Poor medication adherence (MA) may compromise the preventive benefit. Most MA studies primarily concentrate on physician prescription adherence, patients without PAD diagnosis, and non-ATTs. We reviewed the data regarding poor MA of PAD patients to ATT. **Design:** Systematic review Method: Our protocol was based on the PRISMA statement. PubMed, EMBASE, and Cochrane Library were searched from 2000 to June 2023. Publications with a (sub)cohort of PAD patients that reported on patients' MA to ATT were included. The main exclusion criteria were reviews, expert opinions, and, case reports. All articles were reviewed on eligibility and methodological quality by 2 independent researchers. Primary objective was the proportion of patients with poor MA following patient-, pharmacy- or laboratory-reported outcome measurements. Poor MA is a combined intake).

endpoint of primary nonadherence (inability to initiate a prescription), secondary nonadherence (incorrect daily intake), and nonpersistence (discontinuation of daily Results: We identified 274 potentially relevant records of which 10 studies (32,628

patients) were included. Six studies were RCTs, 2 prospective-, and 2 retrospective studies. Most studies scored a moderate risk of bias and had heterogeneous study

designs. Poor MA rates ranged between 2-45%. Higher rates of poor MA were found in studies with longer follow-ups, pharmacy-reported outcome measurements, and registry-based cohorts. **Conclusion:** Heterogeneous study designs create a wide dispersion in the proportions. However, poor MA to ATT was found in approximately one-third of the PAD patients and seemed to increase with longer therapy duration which highlights the magnitude of this societal challenge. Enhancing patients' MA to ATT might be a key element to reduce the risk of AE and, therefore, more attention to MA in clinical and research settings is warranted.

Funding: This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.

PROSPERO registration number: CRD42023431803

1 INTRODUCTION

Peripheral arterial disease (PAD) is associated with a high risk of atherothrombotic events (AE).[1, 2] The annual cardiovascular mortality risk of patients with intermittent claudication is approximately 5% compared to 11.5% for patients with critical limbthreatening ischemia.[3] In contrast to other atherosclerotic diseases such as coronary artery disease and cerebrovascular diseases, the overall long-term risk of major adverse cardiovascular events (MACE) of PAD patients is 2-fold worse.[4, 5] Last decades, revascularisation techniques have been improved which resulted in a 40% reduction in major lower limb amputations, however, the high cardiovascular mortality risk has barely declined.[1, 2, 6, 7]

A cornerstone in PAD MACE management is prevention through pharmacological therapies through lifelong antihypertensives, statins, and antithrombotic therapy (ATT).[1, 2, 8] Medication adherence (MA), which is the ability to take medication following prescriptions, is believed to be an essential factor for pharmacological therapies to be effective.[9, 10] However, approximately 50% of patients with long-term medication due to chronic diseases in developed countries have a poor MA.[11] More specifically, in patients with cardiovascular protective medicines, poor MA was found in 25-80%.[12-17] Nevertheless, the majority of these studies are outdated, focus on physician prescription adherence, primarily concentrate on patients without PAD diagnosis, or non-ATTs. MA is partly influenced by overarching factors such as healthcare systems, but many factors are disease- and patient-related such as clinical symptoms, socioeconomic background, and, medication side effects.[15, 18, 19] This underscores the importance of reporting on MA rates in specific patient populations and medication groups.

MA comprises two main elements: 'adherence' (or 'compliance') and 'persistence'. [9, 15]. No universally accepted consensus exists, however, adherence is mainly used to describe correct daily intake and persistence represents the continuation of daily intake.[9, 15] Adherence can be subdivided into primary- (or initiation) and secondary adherence to differentiate between the ability to initiate a new prescription and the daily intake after initiating the first prescription. Patients are mostly considered adherent when approximately 80% of the intake is as prescribed.[20, 21] MA is measured through patient- (questionnaires), pharmacy- (counting pills, refill records), or biochemical/laboratory-reported outcome measurements (Table S1).[22]

The optimal ATT in PAD patients is still under debate. [1, 8, 23, 24] MA is generally not discussed in trials although poor MA might lead to substantial bias and thus erroneous outcomes. As far as we are aware, there are no systematic analyses regarding MA of PAD patients to ATT . Therefore, we initiated this study to assess medication adherence specifically for ATT in patients with PAD.

(PRISMA)-statement

biochemical/laboratory-reported outcome

(incorrect

daily

(PROSPERO:

METHODS The protocol of this systematic review was based on the Preferred Reporting Items for Systematic Reviews and Meta-Analyses CRD42023431803).[25, 26] Search strategy and study selection The systematic literature search was performed from inception to June 7th, 2023. The bibliographic databases PubMed, Embase.com, and Wiley/Cochrane Library were used. The index terms "Peripheral Arterial Disease", "Antithrombotic Drugs", "Treatment Adherence and Compliance" along with their synonyms and/or closely related words, were included. The search was compiled by a medical database specialist (see Figures S1, S2, and S3). The search results were first deduplicated to which all obtained articles were screened on title and abstract by two independent researchers (EW and BM). Subsequently, the remaining articles were fully reviewed for eligibility and the references were screened for relevant publications (Figure S4). In case of disagreement, the study was reviewed by a third reviewer (CU). Eligible publications contained a (sub)population of adult PAD patients and reported on patients' (non)adherence and/or (non)persistence to ATT. Publications before the year 2000, review articles, expert opinions, case reports, use of polypills, only nurse-led intensified follow-up, and non-English articles were excluded (Figure S4). **Outcome definitions and measurements** The primary objective was the proportion of PAD patients with poor MA following patient-, pharmacy-, or measurements (Table S1). Poor MA includes; primary nonadherence (the inability to prescription), secondary nonadherence initiate а new dosage/timing/frequency after initiating a new prescription), and nonpersistence (discontinuation of the medication intake).[9, 15, 22] Secondary objectives were the proportion of PAD patients with (1) poor MA following pharmacy-reported outcome measurements, (2) primary nonadherence following pharmacy-reported- and (3) all outcome measurements, (4) secondary (short- and long-term) nonadherence following pharmacy-reported- and (5) all outcome measurements, and (6) nonpersistence following pharmacy-reported- and (7) all outcome measurements. Short-term was defined as a maximum follow-up of 6 months and long-term follow-up was defined as more than 6 months.

1 Data extraction and data analysis

The extracted data included; first author, year of publication, study design, country, number of PAD subjects, disease stage, mean age, male-female ratio, type of ATT, type of MA subgroup(s), the proportions of the poor MA, threshold for poor MA, follow-up length, the MA outcome measurement.

The data were retrieved and collected in Review Manager Web (RevMan Web), version 4.14.0., The Cochrane Collaboration, Londen, UK. The number of patients who were adherent/persistent and nonadherent/nonpersistent were extracted from the articles. Subsequently, the proportions of adherence/persistence and nonadherence/nonpersistence were calculated and processed in tables. Clinical homogeneity was assessed based on the study designs and definitions of nonadherence and/or non-persistence.

14 Quality assessment

The Cochrane Risk-of-Bias (ROB) tool was applied to assess the quality of the included randomised controlled trials (RCTs) that reported MA as primary outcome. The Cochrane ROB tool identifies different domains of bias and classifies risk into high-, low-, or unclear risk.[27] The overall quality was deemed high if all domains had a low ROB or 1 domain was unclear. Unclear ROB was considered if $2 \ge$ domains were unclear and high ROB was assigned if $1 \ge$ domain had a high ROB.

For the non-RCTs and RCTs that report MA as a subanalysis, the methodological index for non-randomised studies (MINORS) score was used.[28] This method provides a 12-item list for comparative studies and an 8-item list for noncomparative studies. This score contains 3 classes; 0 (not reported), 1 (reported inadequate), and 2 (reported adequate). The overall quality for non-comparative trials was considered poor if the score was ≤ 8 , moderate between 9-14, and good if ≥ 15 . For the comparative trials, the score ranges were ≤ 15 , 16-22, and ≥ 23 .

29 Patient and public involvement

30 None

49 31

51 32 **RESULTS**

33 Screening process

The search identified 274 potentially relevant records after deduplicating. No articles were added by cross-linking. After reviewing the title and abstract, 227 articles were excluded and 4 articles could not be retrieved. The remaining 45 records were fully screened of which 10 records could be included; 6 RCTs, 2 prospective-, and 2

retrospective studies (Figure S1). In case of conflicting screening decisions, consensus
was found between EW and BM.

Risk-of-bias assessment

5 Three articles were RCTs with MA as the main analysis of the trial and, therefore, the 6 Cochrane ROB tool was used (Table S2). The MINOR-score was used for the other 7 7 articles (Table S3). Overall, most studies had a moderate ROB. Concerns regarding the 8 ROB arise mostly due to patient-reported outcomes and non-adjudicated endpoints 9 that could be easily influenced by knowledge of the intervention. Moreover, most 10 articles did not calculate a sample size based on the MA outcome.

12 Study sample/study characteristics

The characteristics of the included studies are shown in Table 1. In total 32628 PAD patients were analysed. Most studies were executed in Europe, however, the two largest trials (EUCLID and VOYAGER PAD) that accounted for 63% of the included patients were executed in various countries and continents.[29, 30] MA was mostly reported as a sub-analysis. The included trials had rather heterogeneous study designs, making a meta-analysis infeasible.

	1st	Country	YOP	PAD	Severity	ATT	Age	Female	FU
	Author			cohort	disease			(%)	
Ran	domised con	trolled trials							·
1	Cassar [31]	United	2006	67	R1-3 w	A w C or	Mn 66	15 (22)	1M
		Kingdom			EVR	PLB	(R: 43-80)		
2	Haile [32]	Sweden	2022	105	R1-3 w	Any ATT	Md 72	54 (52)	1Y
					EVR/SVR		(IQR: 69-77)		
3	Hess [30]	Multiple	2022	6564	R1-6 w	ASA w PLB	Mn 68	1704 (26)	Md 28M
					EVR/SVR	or DOAC	(IQR: 60-76)		(IQR: 22-34)
4	Jivegard	Sweden	2005	281	R4-6	ASA w PLB	Mn 74	126 (45)	3M
	[33]					or LMWH	(SD:9)		
5	Qvist [34]	Denmark	2019	2051	R 0-6 w/o	Any ATT	Mn 70	0 (0)	5Y
					EVR/SVR		(SD: 2.9)		
6	Weissler	Multiple	2022	13842	R1-6 w/o	C or T	Mn 67	3884 (28)	30M (up to
	[29]				EVR/SVR		(IQR: 59-75)		42 M)
Pros	spective trials								
7	Ferreira	Spain	2010	194	NR	Any APT	Mn 64	43 (22)	1Y
	[35]						(SD: 11.2)		
8	Kremers	Netherlands	2023	246	R1-4	Any APT	Mn 69	105 (43)	1Y
	[36]						(SD: 9.2)		
Ret	rospective stu	idies							
9	Halle [37]	United	2017	100	R1-6 w/o	Any APT	Mn 64	42 (42)	NR
		States			EVR/SVR		(SD: 9.5)		
10	Wawruch	Slovak	2021	9178	R 0-6 w/o	Any APT	Mn 75	5285 (58)	5Y
	[38]	Republic			EVR/SVR				
Tota	al			32628				11258 (35)	

YOP = year of publication; w = with; w/o = with or without; A = acetylsalicylic acid; ATT = antithrombotic therapy;
 DOAC = direct-acting oral anticoagulant; PLB = placebo; LMWH = low molecule weight heparin; C = clopidogrel;
 APT = antiplatelet therapy; NR = not reported; EVR = endovascular revascularisation; SVR = surgical/open
 revascularisation; Mn = mean; Md = median; R = range; ±=standard deviation; () = percentage, M = Months, Y = years.

6 Table 1: Articles eligible for this systematic review 7

8 Medication adherence

Poor MA following all outcome measurements ranged between 2-45% and following
pharmacy-reported measurements between 9-45% (Table 2). One study, however,
reported on all 3 subcategories of poor MA (i.e. primary-, secondary adherence, and
persistence) and reported a total risk of 33%.[34] Overall, higher proportions of poor
MA were found in studies with longer follow-ups, pharmacy-reported outcomes, and
registry-based methods.[32, 34, 38]

One study reported on primary nonadherence based on a pharmacy-reported outcome measurement that occurred in 31% of the study population (Table 3). Short-term secondary nonadherence was reported in 3 articles and ranged between 9-26% (Table 4). Two of the 3 articles applied pharmacy-reported outcome measurement and found rates between 9-21%. Long-term secondary nonadherence, described in 5 articles, showed rates ranging between 5-26% comparable to short-term secondary nonadherence (Table 4). Following the pharmacy-reported outcome measurement long-term secondary nonadherence occurred in 14-20% of the patients. Lastly, nonpersistence was found between 2-33% (Table 5). Nonpersistence within the pharmacy-reported group ranged between 27-33%. Higher rates of nonpersistence were found in studies with longer follow-ups and registry-based methods.

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.

		-		
Nr.	Ref.	Measurement (Table S1)	Poor MA	FU period
Phar	macy ROM			
1	Cassar [31]	Counting returned pills	9%	6 months
2	Haile [32]	Counting pills	30%	1,5 year
3	Qvist [34]	National prescription register	45%*	5 years
4	Wawruch [38]	Counting returned pills	43%	5 years
Phar	macy- and patier	nt ROM		
5	Hess [30]	Interview NVQ and counting	8%	Md 28M (IQR:
		returned pills		22-34)
Patie	nt ROM			
6	Ferreira [35]	Interview (NVQ)	2%	1 year
7	Halle [37]	Brief medication	26%	NR
		questionnaire		
8	Jivegard [33]	Patient diary	26%	3 months
9	Kremers [36]	Morisky Medication	5%	1 year
		Adherence Scale		

10	Weissler [29]	Interview (NR)	10%	30M	(up to ·	42
				(M)		

MA = medication adherence; NVQ = non-validated questionnaire; NR = not reported; Md = median; M = months; IQR = interquartile range; ROM = reported outcome measurements

* Nonpersistence is excluded since the proportion of the patients who were nonadherent and nonpersistent is lacking.

Table 2: Medication adherence

Nr	Ref.	Threshold nonadherence	Nonadherence	FU period
Phar	macy ROM			
1	Qvist [34]	Filling prescription ≤ 120 days	31%	6 months

ROM = reported outcome measurements

Table 3: Primary nonadherence

Nr.	Ref.	Threshold	Nonadherence	FU period
		nonadherence		
		Short-term secondary no	onadherence	
Phar	macy ROM			
1	Cassar [31]	NR	9%	6 months
2	Haile [32]	< 80%	21%	6 month
Patie	nt ROM			
3	Jivegard [33]	NR	26%	3 months
		Long-term secondary	v outcome	
Phar	macy ROM			
1	Haile [32]	< 80%	14%	1,5 year
2	Qvist [34]	< 80%	20%	5 year
3	Wawruch [38]	< 80%	20%	5 year
Patie	nt ROM			
4	Halle [37]	< 80%	26%	NR
5	Kremers [36]	8 points	5%	1 year

NVQ = non-validated questionnaire; ROM = reported outcome measurements

Table 4: Secondary nonadherence

Nr.	Ref.	Threshold	Nonpersistence*	FU period
		nonadherence		
Pharm	nacy ROM			
1	Qvist [34]	< 80%	27%	5 years
2	Wawruch [38]	< 80%	33%	5 years
Phar	nacy- and patien	t ROM		
3	Hess [30]	NR	8%	Md 28M (IQR:
				22-34)
Patier	nt ROM			
4	Ferreira [35]	NR	2%	1 year
5	Weissler [29]	NR	10%	30M (up to 42
				M)

 * Non-persistent due to patients' decisions. The proportion of persistence and nonpersistence might not be 100% due to other trial-related reasons such as major bleeding.

Enseignement Superieur (ABES) Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

3 1	Table 5: Nonpersistence
5	

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

1 DISCUSSION

This systematic review provides an overview of the literature about MA to ATT in patients with PAD. The results demonstrate a poor MA rate of approximately one-third. Despite the variability in poor MA rates, it shows the magnitude of poor MA. Higher rates of poor MA were found in studies with longer follow-ups, pharmacy-reported outcomes, and registry-based methods. The secondary objectives show that all subcategories seem to have a nearly equal share in the overall risk of nonadherence.

Trial designs influence participant burdens which might partly explain the dispersion in MA amongst trials.[39, 40] In this review, 3 articles required minimum effort from participants because of the registry-based or retrospective design compared to the other articles including extensive follow-up, additional injections, and/or blood samples. Designs that required minimum effort, showed the highest rate of poor MA, nonadherence, and/or nonpersistence.[34, 37, 38] In the field of PAD, it is plausible that the likelihood of creating a more representative sample rises as the required effort for patients decreases. Literature shows that PAD patients are frequently precarious which is related to lower socioeconomic status and, therefore, less likely to participate in trials[12, 41-44] Reducing the complexity of trials leads to better understanding, fewer transfers, time commitment, and risk of additional (transfer) costs, resulting in a lower threshold for participation in this population.[40]

Regarding the length of follow-up, the literature shows a tendency for poor MA to increase as the duration of medication use increases.[45-47] This review shows similar results (Tables 2, 4, and 5). One study showed that the highest proportion of nonadherence predominantly occurred between 13 and 24 months with 44% and 35.5% respectively compared to 17% within the first 12 months. This pattern corresponds with the dispersion in our long-term nonadherence results (Table 4).[38]

Additionally, the heterogeneity of the reporting methods, such as the definition of MA and outcome measurements, might contribute to the variety in proportions between studies. MA includes 3 subcategories; primary nonadherence, secondary nonadherence, and nonpersistence. Most articles, except one, researched only nonpersistence and/or secondary nonadherence. This might underestimate the proportion of poor MA by not identifying all categories of MA. The study that distinguished all 3 subcategories reported the highest proportion of poor MA.[34]

Healthcare systems have a major influence on MA.[15, 18, 19, 41] One study showed that participants from North America were more likely to discontinue their medication compared to participants from Europe.[29] Another study executed in North America confirmed that the inability to afford medication was a major reason for

Page 13 of 20

BMJ Open

poor MA.[37] Most European countries have similar healthcare systems that reimburse
necessary health costs.[48]

Regarding patient-related factors, studies that include post-revascularized PAD patients might show slightly higher MA rates.[30-32] One study showed lower longterm secondary nonadherence compared to short-term nonadherence.[32] These patients underwent revascularisation at 6 months follow-up. The severity of the symptoms might affect patients' perception of treatments. However, the literature is ambiguous.[37] Equivocal evidence regarding the impact of patient-related factors on MA is common. Amongst the included studies, subanalyses of patient-related factors show heterogeneous results. [29, 30, 35, 37, 38]

To estimate the individual risk of poor MA, it is of interest whether nonadherence leads to nonpersistence. It seems that adherent and nonadherence patients are both highly at risk for nonpersistence and thus poor MA.[38] The reason given is the lack of awareness regarding the life-long indication for ATT in PAD patients. We advise physicians to discuss MA with PAD patients. Additional research on all subcategories of MA based on registries that use pharmacy refill records and have extensive follow-up are warranted to confirm our findings.

The main strengths of this study are the selected inclusion of trials that include medication adherence of patients with PAD regarding antithrombotic therapies and the distinction between different types of adherence which is clinically relevant when prescribing and discussing antithrombotic treatment. However, this review has a few limitations. Most articles were at moderate risk for bias and a few studies did not mention its thresholds for non-adherence. Moreover, the heterogeneous study designs made a meta-analysis infeasible. Most of the included studies used patient-reported outcome measurements, i.e. questionnaires and interviews, which are at risk for multiple biases such as recall bias leading to potentially misleading low rates of poor MA.[13, 32, 49]

29 CONCLUSION

 30 Studies regarding MA in PAD patients to ATT are scarce and contain 31 heterogeneous designs creating a wide dispersion in MA proportions. However, poor 32 MA to ATT was found in approximately one-third of the PAD patients and seemed to 33 increase with longer duration of ATT use, which highlights the magnitude of this 34 societal challenge.

36 AUTHOR CONTRIBUTIONS:

Enseignement Superieur (ABES) Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

EW: Concept and design, screening, data collection, analyses and interpretation of data, writing of manuscript, final approval.

- BM: Screening, data collection, and analyses, final approval.
 - CU: Concept and design, revision of manuscript, final approval.

GJdB: Concept and design, revision of manuscript, final approval, and is the guarantor.

DATA STATEMENT:

Access to the data is available via the correspondence of this article.

ETHICS APPROVAL:

- Ethical approval was not considered as this review involved only previously published
- data.

REFERENCES

- Aboyans, V., et al., Editor's Choice 2017 ESC Guidelines on the Diagnosis and Treatment of 1. Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS). Eur J Vasc Endovasc Surg, 2018. 55(3): p. 305-368. 2. Twine, C.P., et al., Editor's Choice - European Society for Vascular Surgery (ESVS) 2023 Clinical
- Practice Guidelines on Antithrombotic Therapy for Vascular Diseases. Eur J Vasc Endovasc Surg, 2023. 65(5): p. 627-689.
- 3. van Haelst, S.T.W., et al., Cardiovascular and all-cause mortality in patients with intermittent claudication and critical limb ischaemia. Br J Surg, 2018. 105(3): p. 252-261.
- 4. Welten, G.M., et al., Long-term prognosis of patients with peripheral arterial disease: a comparison in patients with coronary artery disease. J Am Coll Cardiol, 2008. 51(16): p. 1588-96.
- 5. Steg, P.G., et al., One-year cardiovascular event rates in outpatients with atherothrombosis. Jama, 2007. 297(11): p. 1197-206.
- 6. Barnes, J.A., et al., Epidemiology and Risk of Amputation in Patients With Diabetes Mellitus and Peripheral Artery Disease. Arterioscler Thromb Vasc Biol, 2020. 40(8): p. 1808-1817.
- 7. Voci, D., et al., Mortality rate related to peripheral arterial disease: A retrospective analysis of epidemiological data (years 2008-2019). Nutr Metab Cardiovasc Dis, 2023. 33(3): p. 516-522.
- 8. Conte, M.S., et al., Society for Vascular Surgery practice guidelines for atherosclerotic occlusive disease of the lower extremities: management of asymptomatic disease and claudication. J Vasc Surg, 2015. 61(3 Suppl): p. 2s-41s.
 - 9. Cramer, J.A., et al., Medication compliance and persistence: terminology and definitions. Value Health, 2008. 11(1): p. 44-7.
- 10. Simpson, S.H., et al., A meta-analysis of the association between adherence to drug therapy and mortality. Bmj, 2006. 333(7557): p. 15.
- 11. Sabaté, E., Adherence to long-term therapies: evidence for action. 2003: World Health Organization.
| 2 | | | |
|----------|----------|-----|-----------------------------------------------------------------------------------------------------|
| 3 | 1 | 12. | Baroletti, S. and H. Dell'Orfano, Medication adherence in cardiovascular disease. Circulation, |
| 4 | 2 | | 2010. 121 (12): p. 1455-8. |
| 5 | 3 | 13. | Naderi, S.H., J.P. Bestwick, and D.S. Wald, Adherence to drugs that prevent cardiovascular |
| 7 | 4 | | disease: meta-analysis on 376,162 patients. Am J Med, 2012. 125 (9): p. 882-7.e1. |
| ,
8 | 5 | 14. | Memon, R.A., et al., Effect of the Polypill on Adherence and Prevention of Cardiovascular |
| 9 | 6 | | Diseases in Patients With or at High Risk of Cardiovascular Diseases: A Meta-Analysis of |
| 10 | 7 | | Randomized Controlled Trials. Cureus, 2023. 15 (1): p. e34134. |
| 11 | 8 | 15. | Ho, P.M., C.L. Bryson, and J.S. Rumsfeld, Medication adherence: its importance in |
| 12 | 9 | | cardiovascular outcomes. Circulation, 2009. 119(23): p. 3028-35. |
| 13 | 10 | 16. | Flu, H.C., et al., A systematic review of implementation of established recommended |
| 14 | 11 | | secondary prevention measures in patients with PAOD. Eur J Vasc Endovasc Surg, 2010. 39 (1): |
| 16 | 12 | | p. 70-86. |
| 17 | 13 | 17. | Chan, S.L., R. Rajesh, and T.Y. Tang, Evidence-based medical treatment of peripheral arterial |
| 18 | 14 | | disease: A rapid review. Ann Acad Med Singap, 2021. 50(5): p. 411-424. |
| 19 | 15 | 18. | Kardas, P., P. Lewek, and M. Matyjaszczyk, Determinants of patient adherence: a review of |
| 20 | 16 | | systematic reviews. Front Pharmacol, 2013. 4: p. 91. |
| 21 | 17 | 19. | Osterberg, L. and T. Blaschke, Adherence to medication. N Engl J Med, 2005. 353(5): p. 487- |
| 22 | 18 | | 97. |
| 25
24 | 19 | 20. | Svarstad, B.L., et al., The Brief Medication Questionnaire: a tool for screening patient |
| 25 | 20 | | adherence and barriers to adherence. Patient Educ Couns, 1999. 37 (2): p. 113-24. |
| 26 | 21 | 21. | Karve, S., et al., Good and poor adherence: optimal cut-point for adherence measures using |
| 27 | 22 | | administrative claims data. Curr Med Res Opin, 2009. 25 (9): p. 2303-10. |
| 28 | 23 | 22. | Lam, W.Y. and P. Fresco, Medication Adherence Measures: An Overview. Biomed Res Int, |
| 29 | 24 | | 2015. 2015 : p. 217047. |
| 30 | 25 | 23. | Gerhard-Herman, M.D., et al., 2016 AHA/ACC Guideline on the Management of Patients with |
| 31
32 | 26 | | Lower Extremity Peripheral Artery Disease: Executive Summary. Vasc Med, 2017. 22(3): p. |
| 32 | 27 | | Np1-np43. |
| 34 | 28 | 24. | Willems, L.H., et al., Antithrombotic Therapy for Symptomatic Peripheral Arterial Disease: A |
| 35 | 29 | | Systematic Review and Network Meta-Analysis. Drugs, 2022. 82 (12): p. 1287-1302. |
| 36 | 30 | 25. | Page, M.J., et al., PRISMA 2020 explanation and elaboration: updated guidance and |
| 37 | 31 | 20 | exemplars for reporting systematic reviews. Bmj, 2021. 372: p. n160. |
| 38 | 32 | 26. | Retinersen, M.L., et al., PRISMA-S: an extension to the PRISMA Statement for Reporting |
| 39
40 | 33 | 27 | Literature Searches in Systematic Reviews. Syst Rev, 2021. 10(1): p. 39. |
| 40
41 | 34
25 | 27. | Higgins, J.P., et al., The Cochrane Collaboration's tool for assessing risk of blas in randomised |
| 42 | 35 | 20 | (rials. Bm), 2011. 343 : p. 05928. |
| 43 | 30 | 28. | sinn, K., et al., <i>Wethodological index Jor non-randomized studies</i> (minors): development and |
| 44 | 57
20 | 20 | Weissler E H, et al. Understanding Study Drug Discontinuation Through EUCUD Frontiers in |
| 45 | 20 | 29. | Cardiovascular Medicine, 2022. 9 |
| 46 | 39
40 | 20 | Hass C.N. et al. Sex-Resed Differences in Outcomes Following Peripheral Artery |
| 4/
10 | 40 | 50. | Peyascularization: Insights From VOVAGER PAD 1 Am Heart Assoc 2022 11 (12): p. e024655 |
| 40
49 | 41 | 21 | Cassar K et al. Variability in Perpansiveness to Clonidogral in Patients with Intermittent |
| 50 | 42 | 51. | Claudication European journal of vascular and endovascular surgery 2006 32 (1): n. 71-75 |
| 51 | 43
44 | 32 | Haile ST et al. Effects of a nerson-centred nurse-led follow-un programme on adherence to |
| 52 | 45 | 52. | nrescribed medication among natients surgically treated for intermittent claudication: |
| 53 | 46 | | randomized clinical trial Br I Surg 2022 109 (9): n 846-856 |
| 54 | 47 | 33 | livegård. L., et al., Effects of three months of low molecular weight hengrin (daltengrin) |
| 55
56 | 48 | 55. | treatment after bypass surgery for lower limb ischemiaa randomised placeho-controlled |
| 50 | 49 | | double blind multicentre trial. European journal of vascular and endovascular surgery 2005 |
| 58 | 50 | | 29 (2): p. 190-198. |
| 59 | | | |
| 60 | | | |
| | | | |

ו ר			
∠ 3	1	24	Quist Latal Adherance to Proceribed Drugs Among 65,74 Year Old Man Diagnosed with
4	1 2	54.	Abdominal Aartic Anourycm or Darinharal Artarial Dicago in a Scrooning Trial: A VIVA
5	2		Abdominial Abraic Aneurysm or Peripheral Arterial Disease in a Screening That: A VIVA
6	3	25	Substudy. Eur J vasc Endovasc Surg, 2019. 57 (3): p. 442-450.
7	4	35.	Ferreira-Gonzalez, I., et al., Background, Incidence, and predictors of antipidtelet therapy
8	5		discontinuation during the first year after drug-eluting stent implantation. Circulation, 2010.
9	6		122 (10): p. 1017-25.
10	7	36.	Kremers, B.M.M., et al., Inadequate response to antiplatelet therapy in patients with
11	8		peripheral artery disease: a prospective cohort study. Thromb J, 2023. 21 (1): p. 5.
12	9	37.	Halle, T.R., et al., Surgical Intervention for Peripheral Artery Disease Does Not Improve Patient
13	10		Compliance with Recommended Medical Therapy. Ann Vasc Surg, 2018. 46: p. 104-111.
14 17	11	38.	Wawruch, M., et al., Adherence to Antiplatelet Medications among Persistent and Non-
15	12		Persistent Older Patients with Peripheral Arterial Disease. Biomedicines, 2021. 9(12).
10	13	39.	Cameron, D., et al., Assessing Participation Burden in Clinical Trials: Introducing the Patient
18	14		Friction Coefficient. Clin Ther, 2020. 42 (8): p. e150-e159.
19	15	40.	Getz, K., et al., Assessing Patient Participation Burden Based on Protocol Design
20	16		<i>Characteristics</i> . Ther Innov Regul Sci, 2020. 54 (3): p. 598-604.
21	17	41.	De Geest, S. and E. Sabaté, Adherence to long-term therapies: evidence for action. Eur J
22	18		Cardiovasc Nurs. 2003. 2 (4): p. 323.
23	19	42	Information of socioeconomic insecurity in peripheral and
24	20		coronary artery disease natients Med Vasc 2022 47 (5-6): p 220-227
25	20	13	Obm 1 et al. Association of clinical trial participation after myocardial infarction with
26	21	45.	socioeconomic status, clinical characteristics, and outcomes. Eur Hoart I Open, 2021, 1(2): n
27	22		opph/20
28	23	11	Chang P et al. Clinical and socioeconomic factors associated with unrecognized perinheral
29	24	44.	artary disagra Mag 2014 10(4): p 280 206
31	25	4 5	Untery useuse. Vasc Meu, 2014. 19(4). p. 209-290.
32	20	45.	cohort study of medication adherence among older adults. Uppertension, 2011, F9 (F), p. 804
33	27		to the study of medication adherence among order addits. Hypertension, 2011. 36 (5). p. 804-
34	28	10	10. New hydr lafe at all dans tamp adhanana ta suidere a haad aasaa dans annaatisa thaanisa in
35	29	46.	Newby, L.K., et al., Long-term danerence to evidence-based secondary prevention therapies in
36	30		coronary artery alsease. Circulation, 2006. 113 (2): p. 203-12.
37	31	47.	Jackevicius, C.A., M. Mamdani, and J.V. Tu, Adherence with statin therapy in elderly patients
38	32		with and without acute coronary syndromes. Jama, 2002. 288(4): p. 462-7.
39	33	48.	Davis, K., et al., <i>Mirror, mirror on the wall.</i> How the performance of the US Health care
40	34		system compares internationally. New York: CommonWealth Fund, 2014.
41 42	35	49.	Zini, M.L.L. and G. Banfi, A Narrative Literature Review of Bias in Collecting Patient Reported
42 43	36		Outcomes Measures (PROMs). Int J Environ Res Public Health, 2021. 18(23).
44	27		
45	37		
46	38		
47			
48			
49			
50			
51			
52			
53			
54 55			
55			

SUPPLEMENTARY FILE

Tables

Outcome measurements	Specification examples [description]*
pharmacist-reported outcome measurements	Medication Event Monitoring System (MEMS) [Use
	of electronic devices with microchips to record
	medication intake]
	Pharmacy records [Counting returned pills and
	tracking refill patterns]
	Prescription records registers [Tracking all
	dispensed drugs and tracking refill patterns]
Patient-reported outcome measurements	Morisky Medication Adherence Scale (MMAS-8)[1]
	Medication Adherence Report Scale (MARS)[2]
	Simplified Medication Adherence Questionnaire
	(SMAQ)[3]
	Brief Medication Questionnaire (BMQ)[4]
	Other
Biochemical or laboratory outcome	INR, Platelet activity
measurements	

• * This table does not include all existing measurements.

Table S1: Outcome measurements







For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

Cassar, 2006 [8]	2	2	2	2	1	1	2	0	1	2	1	2	18/2 4	Μ
Ferreira, 2010 [9]	2	0	2	2	0	2	0	0	N/A	N/A	N/A	N/A	8/16	Ρ
Halle, 2017 [10]	2	2	2	2	1	1	2	0	N/A	N/A	N/A	N/A	12/1 6	Μ
Hess, 2022 [11]	1	1	2	1	1	2	2	0	N/A	N/A	N/A	N/A	10/1 6	М
Kremers, 2023 [12]	2	1	2	2	1	2	2	0	N/A	N/A	N/A	N/A	12/1 6	Μ
Qvist, 2019 [13]	2	1	1	2	2	2	2	0	N/A	N/A	N/A	N/A	12/1 6	Μ
Wawruch, 2021 [14]	2	2	1	2	2	2	2	0	N/A	N/A	N/A	N/A	13/1 6	Μ

N/A = not applicable; P = Poor; M = Moderate; G = good

Table S3. Risk-of-bias of bias summary for the non-randomised controlled trials following the MINORs-score

Per terier on

Enseignement Superieur (ABES) Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.

Figures

Search	Actions	Details	Query	Results	Time
#4		•	Search: #1 AND #2 AND #3 Sort by: Most Recent	128	08:50:30
#3		•	Search: "Treatment Adherence and Compliance"[Mesh] OR "Medication Adherence"[Mesh]] OR "compliance" [tiab] OR "adherence" [tiab] OR "refus*"[tiab] OR "nonadherence"[tiab] OR "noncompliance"[tiab] Sort by: Most Recent	542,177	08:50:03
#2		• >	Search: "Platelet Aggregation Inhibitors" [Mesh] OR "Platelet Aggregation Inhibitors" [Pharmacological Action] OR "Dual Anti- Platelet Therapy" [Mesh] OR "Platelet aggregation inhibitor*" [tiab] OR "antiplatelet theraps" [tiab] OR "anti platelet theraps" [tiab] OR OR "platelet inhibitor*" [tiab] OR "platelet aggregant*" [tiab] OR "acetylsalicylic acid" [tiab] OR "aspirin" [tiab] OR "paracetamol" [tiab] OR "clopidogrel" [tiab] OR OR "Anticoagulants" [Mesh] OR "Anticoagulants" [Pharmacological Action] OR "Indirect thrombin inhibitor*" [tiab] OR "anti coagulant" [tiab] OR "Fibrinolytic Agents" [Mesh] OR "fibrinolytic agent*" [tiab] OR "fibrinolytic drug*" [tiab] OR "Thrombolytic drug*" [tiab] OR "antithrombotic agent*" [tiab] OR "antithrombotic drug*" [tiab] OR "antithrombotic agent*" [tiab] OR "anticoagulant*" [tiab] OR "Factor Xa inhibitor*" [tiab] OR "Rivaroxaban" [tiab] Sort by: Most Recent	468,945	08:49:49
#1		>	Search: ("Peripheral Arterial Disease" [Mesh] OR "peripheral arterial disease*" [tiab] OR "peripheral artery disease*" [tiab] OR "lower extremity arterial disease*" [tiab] OR "lower extremity artery disease*" [tiab] OR "Chronic Limb-Threatening Ischemia*" [tiab] OR "intermittent claudication*" [tiab] OR "Peripheral Arterial Vascular Disease*" [tiab] OR "peripheral artery occlusive disease*" [tiab] OR "peripheral arterial occlusive disease*" [tiab]) AND ("Peripheral Arterial Disease" [Mesh] OR "peripheral arterial disease*" [tiab] OR "peripheral artery disease*" [tiab] OR "lower extremity arterial disease*" [tiab] OR "lower extremity artery disease*" [tiab] OR "Chronic Limb-Threatening Ischemia*" [tiab] OR "intermittent claudication*" [tiab] OR "Peripheral Arterial Vascular Disease*" [tiab] OR "peripheral artery occlusive disease*" [tiab] OR "Chronic Limb-Threatening Ischemia*" [tiab] OR "peripheral arterial occlusive disease*" [tiab] OR "peripheral arterial occlusive disease*" [tiab]) Sort by: Most Recent	32,848	08:44:08

Figure S1. Search PubMed/MEDLINE



Enseignement Superieur (ABES) Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.



BMJ Open

Enseignement Superieur (ABES) Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.



Figure S3. Search in Embase



Figure S4. The flowchart of the selection process

- 1. Morisky, D.E., et al., *Predictive validity of a medication adherence measure in an outpatient setting.* J Clin Hypertens (Greenwich), 2008. **10**(5): p. 348-54.
- 2. Baroletti, S. and H. Dell'Orfano, *Medication adherence in cardiovascular disease*. Circulation, 2010. **121**(12): p. 1455-8.
- 3. Knobel, H., et al., Validation of a simplified medication adherence questionnaire in a large cohort of HIV-infected patients: the GEEMA Study. Aids, 2002. **16**(4): p. 605-13.
- 4. Svarstad, B.L., et al., *The Brief Medication Questionnaire: a tool for screening patient adherence and barriers to adherence.* Patient Educ Couns, 1999. **37**(2): p. 113-24.
- 5. Haile, S.T., et al., *Effects of a person-centred, nurse-led follow-up programme on adherence to prescribed medication among patients surgically treated for intermittent claudication: randomized clinical trial.* Br J Surg, 2022. **109**(9): p. 846-856.

1		
2		
3		
1		(
т 5		
5		
7		
/		•
8		
9		
10		ė
11		
12		9
13		
14		
15		
16		
17		
18		
19		
20		
21		
22		
23		
24		
25		
26		
27		
28		
29		
30		
31		
37		
22		
31		
25		
26		
30 27		
2/		
20		
39		
40		
41		
42		
43		
44		
45		
46		
47		
48		
49		
50		
51		
52		
53		
54		
55		
56		
57		
58		
59		

- Jivegård, L., et al., Effects of three months of low molecular weight heparin (dalteparin) treatment after bypass surgery for lower limb ischemia--a randomised placebo-controlled double blind multicentre trial. European journal of vascular and endovascular surgery, 2005.
 29(2): p. 190-198.
- 7. Weissler, E.H., et al., *Understanding Study Drug Discontinuation Through EUCLID*. Frontiers in Cardiovascular Medicine, 2022. **9**.
- 8. Cassar, K., et al., *Variability in Responsiveness to Clopidogrel in Patients with Intermittent Claudication.* European journal of vascular and endovascular surgery, 2006. **32**(1): p. 71-75.
- 9. Ferreira-González, I., et al., *Background, incidence, and predictors of antiplatelet therapy discontinuation during the first year after drug-eluting stent implantation.* Circulation, 2010. **122**(10): p. 1017-25.
- 10. Halle, T.R., et al., *Surgical Intervention for Peripheral Artery Disease Does Not Improve Patient Compliance with Recommended Medical Therapy.* Ann Vasc Surg, 2018. **46**: p. 104-111.
- 11. Hess, C.N., et al., *Sex-Based Differences in Outcomes Following Peripheral Artery Revascularization: Insights From VOYAGER PAD.* J Am Heart Assoc, 2022. **11**(12): p. e024655.
- 12. Kremers, B.M.M., et al., *Inadequate response to antiplatelet therapy in patients with peripheral artery disease: a prospective cohort study.* Thromb J, 2023. **21**(1): p. 5.
- 13. Qvist, I., et al., Adherence to Prescribed Drugs Among 65-74 Year Old Men Diagnosed with Abdominal Aortic Aneurysm or Peripheral Arterial Disease in a Screening Trial: A VIVA Substudy. Eur J Vasc Endovasc Surg, 2019. **57**(3): p. 442-450.
- 14. Wawruch, M., et al., Adherence to Antiplatelet Medications among Persistent and Non-Persistent Older Patients with Peripheral Arterial Disease. Biomedicines, 2021. 9(12).

BMJ Open

BMJ Open

Medication adherence of patients with peripheral arterial disease to antithrombotic therapy: a systematic review

Journal:	BMJ Open
Manuscript ID	bmjopen-2024-085056.R2
Article Type:	Original research
Date Submitted by the Author:	08-Dec-2024
Complete List of Authors:	Wegerif, Emilien; University Medical Centre Utrecht, Vascular surgery Mol, Barend; University Medical Centre Utrecht, Department of Vascular Surgery Ünlü, Çağdaş; Noordwest Ziekenhuisgroep, Vascular surgery de Borst, Gert-Jan; University Medical Centre Utrecht, Vascular Surgery
Primary Subject Heading :	Surgery
Secondary Subject Heading:	Cardiovascular medicine, Patient-centred medicine
Keywords:	Medication Adherence, Medication Persistence < Medication Adherence, Medication Review, Systematic Review, Vascular surgery < SURGERY, VASCULAR MEDICINE





I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our <u>licence</u>.

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which <u>Creative Commons</u> licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

terez oni

Enseignement Superieur (ABES) Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies



2									
4	1	Medication adherence of patients with peripheral arterial							
5 6	2	disease to antithrombotic therapy: a systematic review							
7 8	3								
8 9	4	<u>Emilien C. J. Wegerif, MD, MSc^{1A}, Barend Mol, MD^{2A}, Çağdaş Ünlü, MD, Ph.D^{3B}, Gert J. de</u>							
10	5	Borst, MD, Ph.D. ^{4A}							
12	6								
13	7	Affiliations							
14 15	8	A. University Medical Center Utrecht, Department of Vascular Surgery, Circulatory							
16	9	Health, Heidelberglaan 100, 3584CX, Utrecht, the Netherlands							
17 18	10	B. NoordWest Ziekenhuisgroep, Department of Vascular Surgery, Wilhelminalaan 12,							
19	11	1815 JD, Alkmaar, the Netherlands							
20 21	12	Keywards Medication Adherence Treatment Adherence and Compliance Deripheral Arterial							
22	13	Reywords: Medication Adherence, Treatment Adherence and Compliance, Peripheral Artenal							
23	14	Disease, Platelet Aggregation inhibitors, Anticoaguiants, Systematic Review.							
24 25	15	Conflict of interest: None of the authors have any conflicts of interest regarding this article							
26	17	connect of interest. None of the authors have any connects of interest regarding this article.							
27 28	18	Location : This research has been executed at the University Medical Center Utrecht							
29 30 31 32	19								
	20	Funding : This research received no specific grant from any funding agency in the public							
32	21	commercial, or not-for-profit sectors.							
33 34	22								
35	23	Competing interest: There is no competing interest.							
36 37	24								
38	25	Correspondence:							
39 40	26	E.C.J. Wegerif, MD, MSc, PhD candidate, University Medical Center Utrecht, Department of							
40 41	27	Vascular Surgery, Circulatory Health, Heidelberglaan 100, 3584CX, Utrecht, the Netherlands							
42	28	Phone number: +31 887556965							
43 44	29	Email: <u>e.c.j.wegerif@umcutrecht.nl</u>							
45	30								
46 47	31	Word count:Abstract: 300Body: 2100							
48									
49 50									
51									
52 53									
54									
55 56									
57									
58									
59 60									

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

Strengths and limitations of this study This review is based on the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA)-statement and contains a comprehensive search compiled by a medical database specialist. • Studies regarding medication adherence of patients with peripheral arterial disease to antithrombotic therapy are scarce, leading to limited data. • The included trials had rather heterogeneous study designs, making a meta-analysis infeasible and creating a wide dispersion in medication adherence proportions. This review provides insight into the extent of the patient's poor medication adherence which is an addition to the current literature focussing primarily on physician adherence. ABSTRACT Introduction: Patients with peripheral arterial disease (PAD) have a high risk of atherothrombotic events (AE). Antithrombotic therapy (ATT) is an important component in the treatment armamentarium to prevent AE. Poor medication adherence (MA) may compromise the preventive benefit. Most MA studies primarily concentrate on physician prescription adherence, patients without PAD diagnosis, and non-ATTs. We reviewed the data regarding poor MA of PAD patients to ATT. **Design:** Systematic review Method: Our protocol was based on the PRISMA statement. PubMed, EMBASE, and Cochrane Library were searched from 2000 to June 2023. Publications with a (sub)cohort of PAD patients that reported on patients' MA to ATT were included. The main exclusion criteria were reviews, expert opinions, and, case reports. All articles were reviewed on eligibility and methodological quality by 2 independent researchers. Primary objective was the proportion of patients with poor MA following patient-, pharmacy- or laboratory-reported outcome measurements. Poor MA is a combined intake).

endpoint of primary nonadherence (inability to initiate a prescription), secondary nonadherence (incorrect daily intake), and nonpersistence (discontinuation of daily Results: We identified 274 potentially relevant records of which 10 studies (32,628

patients) were included. Six studies were RCTs, 2 prospective-, and 2 retrospective studies. Most studies scored a moderate risk of bias and had heterogeneous study

designs. Poor MA rates ranged between 2-45%. Higher rates of poor MA were found in studies with longer follow-ups, pharmacy-reported outcome measurements, and registry-based cohorts. **Conclusion:** Heterogeneous study designs create a wide dispersion in the proportions. However, poor MA to ATT was found in approximately one-third of the PAD patients and seemed to increase with longer therapy duration, which highlights the magnitude of this societal challenge. Enhancing patients' MA to ATT might be a key element to reducing the risk of AE, and therefore, more attention to MA in clinical and research settings is warranted. Funding: This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors. **PROSPERO registration number:** CRD42023431803

1 INTRODUCTION

Peripheral arterial disease (PAD) is associated with a high risk of atherothrombotic events (AE).[1, 2] The annual cardiovascular mortality risk of patients with intermittent claudication is approximately 5% compared to 11.5% for patients with critical limbthreatening ischemia.[3] In contrast to other atherosclerotic diseases such as coronary artery disease and cerebrovascular diseases, the overall long-term risk of major adverse cardiovascular events (MACE) of PAD patients is 2-fold worse.[4, 5] Last decades, revascularisation techniques have been improved which resulted in a 40% reduction in major lower limb amputations, however, the high cardiovascular mortality risk has barely declined.[1, 2, 6, 7]

A cornerstone in PAD MACE management is prevention through pharmacological therapies through lifelong antihypertensives, statins, and antithrombotic therapy (ATT).[1, 2, 8] Medication adherence (MA), which is the ability to take medication following prescriptions, is believed to be an essential factor for pharmacological therapies to be effective.[9, 10] However, approximately 50% of patients with long-term medication due to chronic diseases in developed countries have a poor MA.[11] More specifically, in patients with cardiovascular protective medicines, poor MA was found in 25-80%.[12-17] Nevertheless, the majority of these studies are outdated, focus on physician prescription adherence, primarily concentrate on patients without PAD diagnosis, or non-ATTs. MA is partly influenced by overarching factors such as healthcare systems, but many factors are disease- and patient-related such as clinical symptoms, socioeconomic background, and, medication side effects.[15, 18, 19] This underscores the importance of reporting on MA rates in specific patient populations and medication groups.

MA comprises two main elements: 'adherence' (or 'compliance') and 'persistence'. [9, 15]. No universally accepted consensus exists, however, adherence is mainly used to describe correct daily intake and persistence represents the continuation of daily intake.[9, 15] Adherence can be subdivided into primary- (or initiation) and secondary adherence to differentiate between the ability to initiate a new prescription and the daily intake after initiating the first prescription. Patients are mostly considered adherent when approximately 80% of the intake is as prescribed.[20, 21] MA is measured through patient- (questionnaires), pharmacy- (counting pills, refill records), or biochemical/laboratory-reported outcome measurements (Table S1).[22]

The optimal ATT in PAD patients is still under debate. [1, 8, 23, 24] MA is generally not discussed in trials although poor MA might lead to substantial bias and thus erroneous outcomes. As far as we know, there are no systematic analyses regarding MA of PAD patients to ATT. Therefore, we initiated this study to assess medication adherence specifically for ATT in patients with PAD.

(PRISMA)-statement

biochemical/laboratory-reported outcome

(incorrect

daily

(PROSPERO:

METHODS The protocol of this systematic review was based on the Preferred Reporting Items for Systematic Reviews and Meta-Analyses CRD42023431803).[25, 26] Search strategy and study selection The systematic literature search was performed from inception to June 7th, 2023. The bibliographic databases PubMed, Embase.com, and Wiley/Cochrane Library were used. The index terms "Peripheral Arterial Disease", "Antithrombotic Drugs", "Treatment Adherence and Compliance" along with their synonyms and/or closely related words, were included. The search was compiled by a medical database specialist (see Figures S1, S2, and S3). The search results were first deduplicated to which all obtained articles were screened on title and abstract by two independent researchers (EW and BM). Subsequently, the remaining articles were fully reviewed for eligibility and the references were screened for relevant publications (Figure S4). In case of disagreement, the study was reviewed by a third reviewer (CU). Eligible publications contained a (sub)population of adult PAD patients and reported on patients' (non)adherence and/or (non)persistence to ATT. Publications before the year 2000, review articles, expert opinions, case reports, use of polypills, only nurse-led intensified follow-up, and non-English articles were excluded (Figure S4). **Outcome definitions and measurements** The primary objective was the proportion of PAD patients with poor MA following patient-, pharmacy-, or measurements (Table S1). Poor MA includes; primary nonadherence (the inability to prescription), secondary nonadherence initiate а new dosage/timing/frequency after initiating a new prescription), and nonpersistence (discontinuation of the medication intake).[9, 15, 22] Secondary objectives were the proportion of PAD patients with (1) poor MA following pharmacy-reported outcome measurements, (2) primary nonadherence following pharmacy-reported- and (3) all outcome measurements, (4) secondary (short- and long-term) nonadherence following pharmacy-reported- and (5) all outcome measurements, and (6) nonpersistence following pharmacy-reported- and (7) all outcome measurements. Short-term was defined as a maximum follow-up of 6 months and long-term follow-up was defined as more than 6 months.

1 Data extraction and data analysis

The extracted data included; first author, year of publication, study design, country,
number of PAD patients, disease stage, mean age, male-female ratio, type of ATT, type
of MA subgroup(s), number of PAD patients that had poor MA per subgroup, number
of PAD patients with overlap between two or more MA subgroups, threshold for poor
MA, follow-up length, and MA outcome measurement.

The data were retrieved and collected in Review Manager Web (RevMan Web), version 4.14.0., The Cochrane Collaboration, Londen, UK. Based on the number of PAD patients with poor MA per subgroup and the total number of PAD patients, the proportions of nonadherence/nonpersistence were calculated per subgroup and processed in the table. For the primary objective, i.e. general poor MA, a separate calculation was made to adjust for patients with two or more kinds of poor MA to avoid overestimation of the general poor MA. Clinical homogeneity was assessed based on the study designs and definitions of nonadherence and/or non-persistence.

16 Quality assessment

The Cochrane Risk-of-Bias (ROB) tool was applied to assess the quality of the included randomised controlled trials (RCTs) that reported MA as primary outcome. The Cochrane ROB tool identifies different domains of bias and classifies risk into high-, low-, or unclear risk.[27] The overall quality was deemed high if all domains had a low ROB or if 1 domain was unclear. Unclear ROB was considered if $2 \ge$ domains were unclear and high ROB was assigned if $1 \ge$ domain had a high ROB. Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

For the non-RCTs and RCTs that report MA as a subanalysis, the methodological index for non-randomised studies (MINORS) score was used.[28] This method provides a 12-item list for comparative studies and an 8-item list for noncomparative studies. This score contains 3 classes; 0 (not reported), 1 (reported inadequate), and 2 (reported adequate). The overall quality for non-comparative trials was considered poor if the score was ≤ 8 , moderate between 9-14, and good if ≥ 15 . For the comparative trials, the score ranges were ≤ 15 , 16-22, and ≥ 23 .

31 Patient and public involvement

32 None

RESULTS

56 35 Screening process

The search identified 274 potentially relevant records after deduplicating. No articles were added by cross-linking. After reviewing the title and abstract, 227 articles were excluded and 4 articles could not be retrieved. The remaining 45 records were fully screened of which 10 records could be included; 6 RCTs, 2 prospective-, and 2
retrospective studies (Figure S1). In case of conflicting screening decisions, consensus
was reached between EW and BM.

5 Risk-of-bias assessment

6 Three articles were RCTs with MA as the main analysis of the trial and, therefore, the 7 Cochrane ROB tool was used (Table S2). The MINOR-score was used for the other 7 8 articles (Table S3). Overall, most studies had a moderate ROB. Concerns regarding the 9 ROB arise mostly due to patient-reported outcomes and non-adjudicated endpoints 10 that could be easily influenced by knowledge of the intervention. Moreover, most 11 articles did not calculate a sample size based on the MA outcome.

13 Study sample/study characteristics

The characteristics of the included studies are shown in Table 1. In total 32628 PAD patients were analysed. Most studies were executed in Europe, however, the two largest trials (EUCLID and VOYAGER PAD) that accounted for 63% of the included patients were executed in various countries and continents.[29, 30] MA was mostly reported as a sub-analysis. The included trials had rather heterogeneous study designs, making a meta-analysis infeasible.

32	
33	

1st Author, YOP	Country	PAD cohort	Severity disease	ATT	Age	Female (%)	FU
Randomised contro	lled trials						
Cassar 2006 [31]	United Kingdom	67	R1-3 w EVR	A w C or PLB	Mn 66 (R: 43-80)	15 (22)	1M
Haile 2022 [32]	Sweden	105	R1-3 w EVR/SVR	Any ATT	Md 72 (IQR: 69-77)	54 (52)	1Y
Hess 2022 [30]	Multiple	6564	R1-6 w EVR/SVR	ASA w PLB or DOAC	Mn 68 (IQR: 60-76)	1704 (26)	Md 28M (IQR: 22-3
Jivegard 2005 [33]	Sweden	281	R4-6	ASA w PLB or LMWH	Mn 74 (SD:9)	126 (45)	3M
Qvist 2019 [34]	Denmark	2051	R 0-6 w/o EVR/SVR	Any ATT	Mn 70 (SD: 2.9)	0 (0)	5Y
Weissler 2022 [29]	Multiple	13842	R1-6 w/o EVR/SVR	C or T	Mn 67 (IQR: 59-75)	3884 (28)	30M (up to 42 M)
Prospective trials			1	1			1
Ferreira 2010 [35]	Spain	194	NR	Any APT	Mn 64 (SD: 11.2)	43 (22)	1Y
Kremers 2023 [36]	Netherlands	246	R1-4	Any APT	Mn 69 (SD: 9.2)	105 (43)	1Y
Retrospective studi	es	1		1		1	1
Halle 2017 [37]	United States	100	R1-6 w/o EVR/SVR	Any APT	Mn 64 (SD: 9.5)	42 (42)	NR
Wawruch 2021 [38]	Slovak Republic	9178	R 0-6 w/o EVR/SVR	Any APT	Mn 75	5285 (58)	5Y
Total		32628				11258 (35)	

22 DOAC = direct-acting oral anticoagulant; PLB = placebo; LMWH = low molecule weight heparin; C = clopidogrel;

23 APT = antiplatelet therapy; NR = not reported; EVR = endovascular revascularisation; SVR = surgical/open

2		
3	1	revascularisation; Mn = mean; Md = median; R = range; ±=standard deviation; () = percentage, M = Months, Y =
4 5	2	years,
6	3	Table 1: Articles eligible for this systematic review
7	4	
8 9	5	Medication adherence
10	6	Poor MA following all outcome measurements ranged between 2-45% and following
11 12	7	pharmacy-reported measurements between 9-45% (Table 2). One study, however,
13	8	reported on all 3 subcategories of poor MA (i.e. primary-, secondary adherence, and
14 15	9	persistence) and reported a total risk of 33%.[34] Overall, higher proportions of poor
16	10	MA were found in studies with longer follow-ups, pharmacy-reported outcomes, and
17 18	11	registry-based methods.[32, 34, 38]
19	12	One study reported on primary nonadherence based on a pharmacy-reported
20 21	13	outcome measurement that occurred in 31% of the study population (Table 2). Short-
22	14	term secondary nonadherence was reported in 3 articles and ranged between 9-26%
23 24	15	(Table 2). Two of the 3 articles applied pharmacy-reported outcome measurement and
25	16	found rates between 9-21%. Long-term secondary nonadherence, described in 5
26 27	17	articles, showed rates ranging between 5-26% comparable to short-term secondary
28 20	18	nonadherence (Table 2). Following the pharmacy-reported outcome measurement
29 30	19	long-term secondary nonadherence occurred in 14-20% of the patients. Lastly,
31 32	20	nonpersistence was found between 2-33% (Table 2). Nonpersistence within the
33	21	pharmacy-reported group ranged between 27-33%. Higher rates of nonpersistence
34 35	22	were found in studies with longer follow-ups and registry-based methods.
36	23	
37		
SÖ		

Nr.	Reference	Nonadherence/ Nonpersistence	Follow-up	Measurement method	Threshold NA
		Poor	medication adherence		
Pha	rmacy ROM	1			
1	Cassar [31]	9%	6M	Counting returned pills	NR
2	Haile [32]	30%	1,5Y	Counting pills	<80%
3	Qvist [34]	45%*	5Υ	National prescription register	Primary NA: filling prescription >120 days. Other: <80%
4	Wawruch [38]	43%	5Y	Counting retuned pills	<80%
Pha	rmacy- and patie	nt ROM			
5	Hess [30]	8%	Md 28M (IQR: 22-34)	Interview NVQ and counting returned pills	NR
Pati	ent ROM	·		· ·	
6	Ferreira [35]	2%	1Y	Interview (NVQ)	NR
7	Halle [37]	26%	NR	Morisky Medication Adherence Scale	8 Points
8	Jivegard [33]	26%	3M	Patient dairy	NR
9	Kremers [36]	5%	1Y	Morisky Medication Adherence Scale	8 Points
10	Weissler [29]	10%	30M (up to 42 M)	Interview	NR
		Pr	imary nonadherence		
1	Qvist [34]	31%	6M	National prescription register	Filling prescription >120 days
		Sec	ondary nonadherence		·
		Short-ter	m secondary nonadhere	ence	
Pha	rmacy ROM	1	1		1
1	Cassar [31]	9%	6M	Counting returned pills	NR
2	Haile [32]	21%	6M	Counting pills	<80%
Pati	ent ROM	2604	214		ND
1	Jivegard	26%	3M	Patient diary	
Dha		Long-1	term secondary outcome	e	
1 Pha		1/1%	1 5V	Counting pills	< 80%
2	Qvist [34]	20%	5Y	National prescription register	<80%
3	Wawruch [38]	20%	5Y	Counting returned pills	<80%
Pati	ent ROM				
4	Halle [37]	26%	NR	Counting pills	<80%
5	Kremers [36]	5%	NR	Morisky Medication Adherence Scale	8 points

			Nonpersistence**		
Pha	rmacy ROM				
1	Qvist [34]	27%	5Y	National prescription register	<80%
2	Wawruch [38]	33%	5Y	Counting returned pills	<80%
Pha	rmacy- and patie	nt ROM			
3	Hess [30]	8%	Md 28M (IQR 22-34)	Interview NVQ and counting returned pills	NR
Pati	ent ROM		·	· · ·	
4	Ferreira [35]	2%	1Y	Interview (NVQ)	NR
5	Weissler [29]	10%	30M (up to 42M)	Interview	NR

• NR = not reported; Md = median; M = months; IQR = interquartile range; ROM = reported outcome measurements, NA = nonadherence, NVQ = non-validated questionnaire

* Nonpersistence is excluded since the proportion of the patients who were nonadherent and nonpersistent is lacking.

** Non-persistent due to patients' decisions.

Table 2: Medication adherence

DISCUSSION

10 This systematic review provides an overview of the literature about MA to ATT in 11 patients with PAD. The results demonstrate a poor MA rate of approximately one-third. 12 Despite the variability in poor MA rates, it shows the magnitude of poor MA. Higher 13 rates of poor MA were found in studies with longer follow-ups, pharmacy-reported 14 outcomes, and registry-based methods. The secondary objectives show that all 15 subcategories seem to have a nearly equal share in the overall risk of nonadherence. Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

Trial designs influence participant burdens which might partly explain the dispersion in MA amongst trials.[39, 40] In this review, 3 articles required minimum effort from participants because of the registry-based or retrospective design compared to the other articles including extensive follow-up, additional injections, and/or blood samples. Designs that required minimum effort, showed the highest rate of poor MA, nonadherence, and/or nonpersistence.[34, 37, 38] In the field of PAD, it is plausible that the likelihood of creating a more representative sample rises as the required effort for patients decreases. Literature shows that PAD patients are frequently precarious which is related to lower socioeconomic status and, therefore, less likely to participate in trials[12, 41-44] Reducing the complexity of trials leads to better understanding, fewer transfers, time commitment, and risk of additional (transfer) costs, resulting in a lower threshold for participation in this population.[40]

Regarding the length of follow-up, the literature shows a tendency for poor MA to increase as the duration of medication use increases.[45-47] This review shows similar results (Tables 2). One study provided a subanalysis (data not uptaken in our table) revealing that the highest proportion of nonadherence predominantly occurred between 13 and 24 months with 44% and 35.5% respectively compared to 17% within the first 12 months.[38] This pattern corresponds with the dispersion in our long-term nonadherence results (Table 2).

Additionally, the heterogeneity of the reporting methods, such as the definition of MA and outcome measurements, might contribute to the variety in proportions between studies. MA includes 3 subcategories; primary nonadherence, secondary nonadherence, and nonpersistence. Most articles, except one, researched only nonpersistence and/or secondary nonadherence. This might underestimate the proportion of poor MA by not identifying all categories of MA. The study that distinguished all 3 subcategories reported the highest proportion of poor MA.[34]

Healthcare systems have a major influence on MA.[15, 18, 19, 41] One study showed that participants from North America were more likely to discontinue their medication compared to participants from Europe.[29] Another study executed in North America confirmed that the inability to afford medication was a major reason for poor MA.[37] Most European countries have similar healthcare systems that reimburse necessary health costs.[48]

Regarding patient-related factors, studies that include post-revascularized PAD patients might show slightly higher MA rates.[30-32] One study showed lower long-term secondary nonadherence compared to short-term nonadherence.[32] These patients underwent revascularisation at 6 months follow-up. The severity of the symptoms might affect patients' perception of treatments. However, the literature is ambiguous.[37] Equivocal evidence regarding the impact of patient-related factors on MA is common. Amongst the included studies, subanalyses of patient-related factors show heterogeneous results.[29, 30, 35, 37, 38]

To estimate the individual risk of poor MA, it is of interest whether nonadherence leads to nonpersistence. It seems that adherent and nonadherence patients are both highly at risk for nonpersistence and thus poor MA.[38] The reason given is the lack of awareness regarding the life-long indication for ATT in PAD patients. We advise physicians to discuss MA with PAD patients. Additional research on all subcategories of MA based on registries that use pharmacy refill records and have extensive follow-up are warranted to confirm our findings.

The main strengths of this study are the selected inclusion of trials that include medication adherence of patients with PAD regarding antithrombotic therapies and

the distinction between different types of adherence which is clinically relevant when prescribing and discussing antithrombotic treatment. However, this review has a few limitations. Six out of the 10 included articles are RCTs. RCTs may not reflect real-world adherence as these patients are often more closely monitored, and therefore, more motivated. Most articles were at moderate risk for bias and a few studies did not mention its thresholds for non-adherence. Moreover, the heterogeneous study designs made a meta-analysis infeasible. Most of the included studies used patient-reported outcome measurements, i.e. questionnaires and interviews, which are at risk for multiple biases such as recall bias leading to potentially misleading low rates of poor MA.[13, 32, 49]

CONCLUSION

Studies regarding MA in PAD patients to ATT are scarce and contain heterogeneous designs creating a wide dispersion in MA proportions. However, poor MA to ATT was found in approximately one-third of the PAD patients and seemed to increase with longer duration of ATT use, which highlights the magnitude of this societal challenge.

AUTHOR CONTRIBUTIONS:

EW: Concept and design, screening, data collection, analyses and interpretation of data, writing of manuscript, final approval.

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

- BM: Screening, data collection, and analyses, final approval.
- CU: Concept and design, revision of manuscript, final approval.
- GJdB: Concept and design, revision of manuscript, final approval, and is the guarantor.

DATA STATEMENT:

- Access to the data is available via the correspondence of this article.

ETHICS APPROVAL:

Ethical approval was not considered as this review involved only previously published data.

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.

2			
3	1	REFE	ERENCES
4	2	1	Abovans V et al Editor's Choice - 2017 ESC Guidelines on the Diagnosis and Treatment of
5	2	1.	Perinheral Arterial Diseases in collaboration with the European Society for Vascular Surgery
7	4		(FSVS) Fur I Vasc Endovasc Surg 2018 55 (3): p. 305-368
, 8	5	2	Twine C.P. et al. Editor's Choice - European Society for Vascular Surgery (ESVS) 2023 Clinical
9	6	۷.	Practice Guidelines on Antithromhotic Therapy for Vascular Diseases Fur I Vasc Endovasc
10	7		Surg 2023 65(5): n 627-689
11	2 2	3	van Haelst STW et al. Cardiovascular and all-cause mortality in natients with intermittent
12	0 0	Э.	claudication and critical limb ischaemia Br I Surg 2018 105 (3): p 252-261
13	10	Л	Welten G M et al. Long-term prognosis of nationts with peripheral arterial disease: a
14	11	4.	comparison in patients with coronary artery disease 1 Am Coll Cardiol 2008 51 (16): p. 1588-
15	12		06
10	12	5	Steg PG et al. One-year cardiovascular event rates in outpatients with atherothromhosis
18	14	Э.	1 Jamp = 2007 297 (11): p 1107-206
19	14	6	Barnes IA et al Enidemiology and Rick of Amnutation in Patients With Diabetes Mellitus
20	15	0.	and Perinheral Artery Disease Arterioscler Thromb Vasc Biol 2020 40 (8): p. 1808-1817
21	17	7	Voci D et al. Mortality rate related to peripheral arterial disease: A retrospective analysis of
22	18	/.	enidemiological data (years 2008-2010) Nutr Metab Cardiovasc Dis 2023 33 (3): p. 516-522
23	10	Q	Conto MS, et al. Society for Vascular Surgery practice guidelines for atheroscleratic
24	20	0.	occlusive disease of the lower extremities: management of asymptomatic disease and
25 26	20		claudication 1/Jase Surg 2015 61/3 Suppl): p. 2s-41s
20	21	٩	Cramer 1 A st al Medication compliance and persistence: terminology and definitions
28	22	5.	Value Health 2008 11(1): n 44-7
29	23	10	Simpson SH et al. A meta-analysis of the association between adherence to drug therapy
30	24	10.	and mortality Bmi 2006 222(7557): n 15
31	25	11	Sabaté E Adherence to long-term theranies: evidence for action 2003: World Health
32	20	11.	Organization
33	27	12	Baroletti S and H Dell'Orfano, Medication adherence in cardiovascular disease. Circulation
54 35	20	12.	2010 121 (12): n 1/155-8
36	30	13	Naderi S H. I.P. Bestwick and D.S. Wald Adherence to drugs that prevent cardiovascular
37	31	15.	disease: meta-analysis on 376 162 natients. Am I Med 2012 125 (9): n. 882-7 e1
38	32	14	Memon R A et al. Effect of the Polynill on Adherence and Prevention of Cardiovascular
39	33	14.	Diseases in Patients With or at High Risk of Cardiovascular Diseases: A Meta-Analysis of
40	34		Randomized Controlled Trials Cureus 2023 15(1): n e34134
41	35	15	Ho P.M. C.L. Bryson and LS Rumsfeld Medication adherence: its importance in
42	36	10.	cardiovascular outcomes Circulation 2009 119 (23): p 3028-35
45 44	37	16.	Flu, H C., et al., A systematic review of implementation of established recommended
45	38	10.	secondary prevention measures in patients with PAOD Fur I Vasc Endovasc Surg 2010, 39 (1):
46	39		n 70-86
47	40	17.	Chan, S.L., R. Raiesh, and T.Y. Tang. <i>Evidence-based medical treatment of peripheral arterial</i>
48	41	±7.	disease: A ranid review. Ann Acad Med Singan, 2021, 50 (5): p. 411-424
49	42	18	Kardas, P., P. Lewek, and M. Matyjaszczyk, Determinants of national adherence: a review of
50	43	10.	systematic reviews. Front Pharmacol. 2013. 4 : p. 91.
51	44	19.	Osterberg, L. and T. Blaschke, Adherence to medication. N Engl J Med. 2005. 353(5): p. 487-
52 52	45		97.
54	46	20	Svarstad, B.L., et al., The Brief Medication Questionnaire: a tool for screening natient
55	47	_0.	adherence and barriers to adherence. Patient Educ Couns. 1999 37 (2): n. 113-24
56	48	21	Karve, S., et al., Good and poor adherence: optimal cut-point for adherence measures using
57	49		administrative claims data. Curr Med Res Opin. 2009. 25(9): p. 2303-10.
58	50	22.	Lam. W.Y. and P. Fresco. <i>Medication Adherence Measures: An Overview</i> . Biomed Res Int.
59	51		2015. 2015 : p. 217047.
60	<u> </u>		p

BMJ Open

2			
3	1	23.	Gerhard-Herman, M.D., et al., 2016 AHA/ACC Guideline on the Management of Patients with
4	2		Lower Extremity Peripheral Artery Disease: Executive Summary. Vasc Med, 2017. 22(3): p.
5	3		Np1-np43.
6	4	24.	Willems, L.H., et al., Antithrombotic Therapy for Symptomatic Peripheral Arterial Disease: A
/	5		Systematic Review and Network Meta-Analysis, Drugs, 2022, 82 (12); p. 1287-1302.
ð	6	25.	Page M.L. et al., PRISMA 2020 explanation and elaboration: undated auidance and
9 10	7	_0.	exemplars for reporting systematic reviews Bmi 2021 372 n n160
11	, 8	26	Rethlefsen M L et al PRISMA-S: an extension to the PRISMA Statement for Reporting
12	٥ ۵	20.	Literature Searches in Systematic Reviews Syst Rev 2021 10(1): n 30
13	10	77	Higging I.D. at al. The Cochrane Collaboration's tool for associating rick of higs in randomicad
14	10	27.	trials Dmi 2011 242 n dE028
15	11	20	(1/u/s. Dill), 2011. 343 . p. 03926.
16	12	28.	Silm, K., et al., <i>Wethodological index for non-randomized studies (minors): development and</i>
17	13	•••	validation of a new instrument. ANZ J Surg, 2003. 73 (9): p. 712-6.
18	14	29.	Weissler, E.H., et al., Understanding Study Drug Discontinuation Through EUCLID. Frontiers in
19	15		Cardiovascular Medicine, 2022. 9.
20	16	30.	Hess, C.N., et al., Sex-Based Differences in Outcomes Following Peripheral Artery
21	17		<i>Revascularization: Insights From VOYAGER PAD.</i> J Am Heart Assoc, 2022. 11 (12): p. e024655.
22	18	31.	Cassar, K., et al., Variability in Responsiveness to Clopidogrel in Patients with Intermittent
25 24	19		<i>Claudication</i> . European journal of vascular and endovascular surgery, 2006. 32 (1): p. 71-75.
24 25	20	32.	Haile, S.T., et al., Effects of a person-centred, nurse-led follow-up programme on adherence to
25	21		prescribed medication among patients surgically treated for intermittent claudication:
27	22		randomized clinical trial. Br J Surg, 2022. 109 (9): p. 846-856.
28	23	33.	Jivegård, L., et al., Effects of three months of low molecular weight heparin (dalteparin)
29	24		treatment after bypass surgery for lower limb ischemiaa randomised placebo-controlled
30	25		double blind multicentre trial. European journal of vascular and endovascular surgery, 2005.
31	26		29 (2): p. 190-198.
32	27	34.	Qvist, I., et al., Adherence to Prescribed Drugs Among 65-74 Year Old Men Diggnosed with
33	28		Abdominal Aortic Aneurysm or Peripheral Arterial Disease in a Screenina Trial: A VIVA
34	29		Substudy, Eur J Vasc Endovasc Surg. 2019, 57 (3): p. 442-450.
35	30	35	Ferreira-González L et al Background incidence and predictors of antiplatelet therapy
36	31	55.	discontinuation during the first year after drug-eluting stent implantation Circulation 2010
3/ 20	32		122 (10): n 1017-25
20 20	32	36	Kremers BMM et al Inadequate response to antiplatelet therapy in patients with
40	24	50.	norinheral artery diseases a prospective schort study. Thromb L 2022, 21 (1): p. 5
41	54 25	27	Hollo T. D., et al. Surgical Intervention for Derinberg Artery Disasse Dees Not Improve Datient
42	35	57.	Gampliance with Decomposed of Medical Therapy, App Medical Surg 2018, 46, p. 104, 111
43	30	20	Compliance with Recommended Medical Therapy. Ann Vasc Surg, 2018. 46 : p. 104-111.
44	37	38.	wawruch, M., et al., Adherence to Antiplatelet Medications among Persistent and Non-
45	38	20	Persistent Older Patients with Peripheral Arterial Disease. Biomedicines, 2021. 9(12).
46	39	39.	Cameron, D., et al., Assessing Participation Burden in Clinical Trials: Introducing the Patient
47	40		Friction Coefficient. Clin Ther, 2020. 42 (8): p. e150-e159.
48	41	40.	Getz, K., et al., Assessing Patient Participation Burden Based on Protocol Design
49	42		<i>Characteristics</i> . Ther Innov Regul Sci, 2020. 54 (3): p. 598-604.
50	43	41.	De Geest, S. and E. Sabaté, Adherence to long-term therapies: evidence for action. Eur J
51	44		Cardiovasc Nurs, 2003. 2 (4): p. 323.
52	45	42.	Joly, M., et al., Comparative evaluation of socioeconomic insecurity in peripheral and
54	46		coronary artery disease patients. J Med Vasc, 2022. 47(5-6): p. 220-227.
55	47	43.	Ohm, J., et al., Association of clinical trial participation after myocardial infarction with
56	48		socioeconomic status, clinical characteristics, and outcomes. Eur Heart J Open, 2021. 1(2): p.
57	49		oeab020.
58	50	44.	Chang, P., et al., Clinical and socioeconomic factors associated with unrecognized peripheral
59	51		artery disease. Vasc Med, 2014. 19 (4): p. 289-296.
60			

2	
2	
3	
4	
5	
2	
6	
7	
8	
0	
9	
10	
11	
11	
12	
13	
14	
17	
15	
16	
17	
10	
18	
19	
20	
20	
21	
22	
23	
24	
24	
25	
26	
27	
27	
28	
29	
20	
50	
31	
32	
22	
33	
34	
35	
26	
50	
37	
38	
20	
39	
40	
41	
⊿ ว	
-12	
43	
44	
45	
ر ب	
46	
47	
48	
40	
49	
50	
51	
51	
52	
53	
54	
55	
56	
57	
57	
58	

12 13

1

45. Krousel-Wood, M., et al., Predictors of decline in medication adherence: results from the 1 2 cohort study of medication adherence among older adults. Hypertension, 2011. 58(5): p. 804-3 10.

- 4 46. Newby, L.K., et al., Long-term adherence to evidence-based secondary prevention therapies in 5 coronary artery disease. Circulation, 2006. 113(2): p. 203-12.
- 6 Jackevicius, C.A., M. Mamdani, and J.V. Tu, Adherence with statin therapy in elderly patients 47. 7 with and without acute coronary syndromes. Jama, 2002. 288(4): p. 462-7.
- 8 Davis, K., et al., Mirror, mirror on the wall. How the performance of the US Health care 48. 9 system compares internationally. New York: CommonWealth Fund, 2014.
 - , A PROM. 10 49. Zini, M.L.L. and G. Banfi, A Narrative Literature Review of Bias in Collecting Patient Reported 11 Outcomes Measures (PROMs). Int J Environ Res Public Health, 2021. 18(23).

Enseignement Superieur (ABES) Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies

SUPPLEMENTARY FILE

Tables

Outcome measurements	Specification examples [description]*
pharmacist-reported outcome measurements	Medication Event Monitoring System (MEMS) [Use
	of electronic devices with microchips to record
	medication intake]
	Pharmacy records [Counting returned pills and
	tracking refill patterns]
	Prescription records registers [Tracking all
	dispensed drugs and tracking refill patterns]
Patient-reported outcome measurements	Morisky Medication Adherence Scale (MMAS-8)[1]
	Medication Adherence Report Scale (MARS)[2]
	Simplified Medication Adherence Questionnaire
	(SMAQ)[3]
	Brief Medication Questionnaire (BMQ)[4]
	Other
Biochemical or laboratory outcome	INR, Platelet activity
measurements	

• * This table does not include all existing measurements.

Table S1: Outcome measurements







For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

Cassar, 2006 [8]	2	2	2	2	1	1	2	0	1	2	1	2	18/2 4	Μ
Ferreira, 2010 [9]	2	0	2	2	0	2	0	0	N/A	N/A	N/A	N/A	8/16	Ρ
Halle, 2017 [10]	2	2	2	2	1	1	2	0	N/A	N/A	N/A	N/A	12/1 6	Μ
Hess, 2022 [11]	1	1	2	1	1	2	2	0	N/A	N/A	N/A	N/A	10/1 6	М
Kremers, 2023 [12]	2	1	2	2	1	2	2	0	N/A	N/A	N/A	N/A	12/1 6	Μ
Qvist, 2019 [13]	2	1	1	2	2	2	2	0	N/A	N/A	N/A	N/A	12/1 6	Μ
Wawruch, 2021 [14]	2	2	1	2	2	2	2	0	N/A	N/A	N/A	N/A	13/1 6	Μ

N/A = not applicable; P = Poor; M = Moderate; G = good

Table S3. Risk-of-bias of bias summary for the non-randomised controlled trials following the MINORs-score

Per terier on

Enseignement Superieur (ABES) Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.

Figures

Search	Actions	Details	Query	Results	Time
#4		•	Search: #1 AND #2 AND #3 Sort by: Most Recent	128	08:50:30
#3		•	Search: "Treatment Adherence and Compliance"[Mesh] OR "Medication Adherence"[Mesh]] OR "compliance" [tiab] OR "adherence" [tiab] OR "refus*"[tiab] OR "nonadherence"[tiab] OR "noncompliance"[tiab] Sort by: Most Recent	542,177	08:50:03
#2		• >	Search: "Platelet Aggregation Inhibitors" [Mesh] OR "Platelet Aggregation Inhibitors" [Pharmacological Action] OR "Dual Anti- Platelet Therapy" [Mesh] OR "Platelet aggregation inhibitor*" [tiab] OR "antiplatelet theraps" [tiab] OR "anti platelet theraps" [tiab] OR OR "platelet inhibitor*" [tiab] OR "platelet aggregant*" [tiab] OR "acetylsalicylic acid" [tiab] OR "aspirin" [tiab] OR "paracetamol" [tiab] OR "clopidogrel" [tiab] OR OR "Anticoagulants" [Mesh] OR "Anticoagulants" [Pharmacological Action] OR "Indirect thrombin inhibitor*" [tiab] OR "anti coagulant" [tiab] OR "Fibrinolytic Agents" [Mesh] OR "fibrinolytic agent*" [tiab] OR "fibrinolytic drug*" [tiab] OR "Thrombolytic drug*" [tiab] OR "antithrombotic agent*" [tiab] OR "antithrombotic drug*" [tiab] OR "antithrombotic agent*" [tiab] OR "anticoagulant*" [tiab] OR "Factor Xa inhibitor*" [tiab] OR "Rivaroxaban" [tiab] Sort by: Most Recent	468,945	08:49:49
#1		>	Search: ("Peripheral Arterial Disease" [Mesh] OR "peripheral arterial disease*" [tiab] OR "peripheral artery disease*" [tiab] OR "lower extremity arterial disease*" [tiab] OR "lower extremity artery disease*" [tiab] OR "Chronic Limb-Threatening Ischemia*" [tiab] OR "intermittent claudication*" [tiab] OR "Peripheral Arterial Vascular Disease*" [tiab] OR "peripheral artery occlusive disease*" [tiab] OR "peripheral arterial occlusive disease*" [tiab] AND ("Peripheral Arterial Disease" [Mesh] OR "peripheral arterial disease*" [tiab] OR "peripheral artery disease*" [tiab] OR "lower extremity arterial disease*" [tiab] OR "lower extremity artery disease*" [tiab] OR "Chronic Limb-Threatening Ischemia*" [tiab] OR "intermittent claudication*" [tiab] OR "Peripheral Arterial Vascular Disease*" [tiab] OR "peripheral artery occlusive disease*" [tiab] OR "Chronic Limb-Threatening Ischemia*" [tiab] OR "peripheral arterial occlusive disease*" [tiab] Sort by: Most Recent	32,848	08:44:08

Figure S1. Search PubMed/MEDLINE



Enseignement Superieur (ABES) Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.



BMJ Open

Enseignement Superieur (ABES) Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.



Figure S3. Search in Embase



Figure S4. The flowchart of the selection process

- 1. Morisky, D.E., et al., *Predictive validity of a medication adherence measure in an outpatient setting.* J Clin Hypertens (Greenwich), 2008. **10**(5): p. 348-54.
- 2. Baroletti, S. and H. Dell'Orfano, *Medication adherence in cardiovascular disease*. Circulation, 2010. **121**(12): p. 1455-8.
- 3. Knobel, H., et al., *Validation of a simplified medication adherence questionnaire in a large cohort of HIV-infected patients: the GEEMA Study.* Aids, 2002. **16**(4): p. 605-13.
- 4. Svarstad, B.L., et al., *The Brief Medication Questionnaire: a tool for screening patient adherence and barriers to adherence.* Patient Educ Couns, 1999. **37**(2): p. 113-24.
- 5. Haile, S.T., et al., *Effects of a person-centred, nurse-led follow-up programme on adherence to prescribed medication among patients surgically treated for intermittent claudication: randomized clinical trial.* Br J Surg, 2022. **109**(9): p. 846-856.

1		
2		
3		
1		(
т 5		
5		
7		
/		•
8		
9		
10		ė
11		
12		9
13		
14		
15		
16		
17		
18		
19		
20		
21		
22		
23		
24		
25		
26		
27		
28		
29		
30		
31		
37		
22		
31		
25		
26		
30 27		
2/		
20		
39		
40		
41		
42		
43		
44		
45		
46		
47		
48		
49		
50		
51		
52		
53		
54		
55		
56		
57		
58		
59		

- Jivegård, L., et al., Effects of three months of low molecular weight heparin (dalteparin) treatment after bypass surgery for lower limb ischemia--a randomised placebo-controlled double blind multicentre trial. European journal of vascular and endovascular surgery, 2005.
 29(2): p. 190-198.
- 7. Weissler, E.H., et al., *Understanding Study Drug Discontinuation Through EUCLID*. Frontiers in Cardiovascular Medicine, 2022. **9**.
- 8. Cassar, K., et al., *Variability in Responsiveness to Clopidogrel in Patients with Intermittent Claudication.* European journal of vascular and endovascular surgery, 2006. **32**(1): p. 71-75.
- 9. Ferreira-González, I., et al., *Background, incidence, and predictors of antiplatelet therapy discontinuation during the first year after drug-eluting stent implantation.* Circulation, 2010. **122**(10): p. 1017-25.
- 10. Halle, T.R., et al., *Surgical Intervention for Peripheral Artery Disease Does Not Improve Patient Compliance with Recommended Medical Therapy.* Ann Vasc Surg, 2018. **46**: p. 104-111.
- 11. Hess, C.N., et al., *Sex-Based Differences in Outcomes Following Peripheral Artery Revascularization: Insights From VOYAGER PAD.* J Am Heart Assoc, 2022. **11**(12): p. e024655.
- 12. Kremers, B.M.M., et al., *Inadequate response to antiplatelet therapy in patients with peripheral artery disease: a prospective cohort study.* Thromb J, 2023. **21**(1): p. 5.
- 13. Qvist, I., et al., Adherence to Prescribed Drugs Among 65-74 Year Old Men Diagnosed with Abdominal Aortic Aneurysm or Peripheral Arterial Disease in a Screening Trial: A VIVA Substudy. Eur J Vasc Endovasc Surg, 2019. **57**(3): p. 442-450.
- 14. Wawruch, M., et al., Adherence to Antiplatelet Medications among Persistent and Non-Persistent Older Patients with Peripheral Arterial Disease. Biomedicines, 2021. 9(12).

BMJ Open

BMJ Open

Medication adherence of patients with peripheral arterial disease to antithrombotic therapy: a systematic review

Journal:	BMJ Open
Manuscript ID	bmjopen-2024-085056.R3
Article Type:	Original research
Date Submitted by the Author:	20-Jan-2025
Complete List of Authors:	Wegerif, Emilien; University Medical Centre Utrecht, Vascular surgery Mol, Barend; University Medical Centre Utrecht, Department of Vascular Surgery Ünlü, Çağdaş; Noordwest Ziekenhuisgroep, Vascular surgery de Borst, Gert-Jan; University Medical Centre Utrecht, Vascular Surgery
Primary Subject Heading :	Surgery
Secondary Subject Heading:	Cardiovascular medicine, Patient-centred medicine
Keywords:	Medication Adherence, Medication Persistence < Medication Adherence, Medication Review, Systematic Review, Vascular surgery < SURGERY, VASCULAR MEDICINE





I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our <u>licence</u>.

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which <u>Creative Commons</u> licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

terez oni

Enseignement Superieur (ABES) Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies



2								
4	1	Medication adherence of patients with peripheral arterial						
5 6	2	disease to antithrombotic therapy: a systematic review						
7 8	3							
9	4	<u>Emilien C. J. Wegerif, MD, MSc^{1A}, Barend Mol, MD^{2A}, Çağdaş Ünlü, MD, Ph.D^{3B}, Gert J. de</u>						
10	5	Borst, MD, Ph.D. ^{4A}						
12	6							
13	7	Affiliations						
14	8	A. University Medical Center Utrecht, Department of Vascular Surgery, Circulatory						
16	9	Health, Heidelberglaan 100, 3584CX, Utrecht, the Netherlands						
17 18	10	B. Noordwest Ziekennuisgroep, Department of Vascular Surgery, Wilneiminalaan 12,						
19	11	1815 JD, Alkmaar, the Nethenands						
20 21	12	Konwords: Madication Adherence, Treatment Adherence and Compliance, Berinheral Arterial						
22	17	Disease Platelet Aggregation Inhibitors, Anticoagulants, Systematic Poview						
23 24	14	Disease, Flatelet Aggregation finibitors, Anticoagularits, Systematic Review.						
24 25	16	Conflict of interest: None of the authors have any conflicts of interest regarding this article						
26	17	connect of interest. None of the authors have any connects of interest regarding this article.						
27 28	18	Location : This research has been executed at the University Medical Center Utrecht						
29	19							
30 31	20	Funding : This research received no specific grant from any funding agency in the public						
32	21	commercial, or not-for-profit sectors.						
33 34	22							
35	23	Competing interest: There is no competing interest.						
36 37	24							
38	25	Correspondence:						
39 40	26	E.C.J. Wegerif, MD, MSc, PhD candidate, University Medical Center Utrecht, Department of						
40 41	27	Vascular Surgery, Circulatory Health, Heidelberglaan 100, 3584CX, Utrecht, the Netherlands						
42	28	Phone number: +31 887556965						
43 44	29	Email: <u>e.c.j.wegerif@umcutrecht.nl</u>						
45	30							
46 47	31	Word count:Abstract: 300Body: 2100						
48								
49 50								
51								
52 53								
54								
55 56								
50 57								
58								
59 60								

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

1 2		
3	1	Strengths and limitations of this study
4 5	2	• This review is based on the Preferred Reporting Items for Systematic Reviews
6	3	and Meta-Analyses (PRISMA)-statement and contains a comprehensive search
7 8	4	compiled by a medical database specialist.
9	5	• Studies regarding medication adherence of patients with peripheral arterial
10 11	6	disease to antithrombotic therapy are scarce, leading to limited data.
12	7	• The included trials had rather heterogeneous study designs, making a meta-
13 14	8	analysis infeasible and creating a wide dispersion in medication adherence
15	9	proportions.
16 17	10	• This review provides insight into the extent of the patient's poor medication
18	11	adherence which is an addition to the current literature focussing primarily on
19 20	12	physician adherence.
21	13	
22 23	14	ABSTRACT
24	15	Objectives: Antithrombotic therapy (ATT) prevents atherothrombotic events (AE) in
25 26	16	patients with peripheral arterial disease (PAD). However, the benefit may be
27	17	compromised by poor medication adherence (MA). Therefore, our primary objective
28 29	18	was the proportion of PAD patients with poor MA in literature following patient-
30	10	nharmacy- or laboratory-reported outcome measurements. Poor MA is a combined
31 32	20	outcome of primary ponedberence (inability to initiate a prescription) secondary
33	20	nonadherence (incorrect daily intake) and nonpersistence (discontinuation of daily
34 35	21	intako)
36	22	intake).
37 38	25	Decign: Systematic review based on the PRISMA statement
39	24	Design. Systematic review based on the PRISINA statement.
40 41	25	Deta courses DubMad EMPASE and Cashrana Library wars soorshad from 2000 to
42	26	Data sources: Publiked, EMBASE, and Cochrane Library were searched from 2000 to
43 44	27	June 2023.
45	28	First With a day to D. Island and the control of DAD and the transmission of the
46 47	29	Eligibility criteria: Publications with a (sub)conort of PAD patients that reported on
48	30	patients' MA to ATT were included.
49 50	31	
51	32	Data extraction and synthesis: All articles were reviewed on eligibility and
52	33	methodological quality by 2 independent researchers. The data were retrieved and
55 54	34	collected in Review Manager Web and the percentages were calculated per subgroup.
55 56	35	Risk of bias was assessed by using the Cochrane Risk-of-Bias tool for randomised
50 57	36	controlled trials (RCT) and the methodological index for non-randomised studies
58	37	(MINORS) score for non-RCTs.
59 60	38	

Enseignement Superieur (ABES) Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.

Results: We identified 274 potential records of which 10 studies (32,628 patients) were included. Six studies were RCTs, 2 prospective-, and 2 retrospective studies. Most studies scored a moderate risk of bias and had heterogeneous study designs. Poor MA rates ranged between 2-45%. Higher rates of poor MA were found in studies with longer follow-ups, pharmacy-reported outcome measurements, and registry-based cohorts.

Conclusion: Heterogeneous study designs create a wide dispersion in the proportions. However, poor MA to ATT was found in approximately one-third of the PAD patients and seemed to increase with longer therapy duration, which highlights the magnitude of this societal challenge. Enhancing patients' MA to ATT might be a key element to reducing the risk of AE, and therefore, more attention to MA in clinical and research settings is warranted.

Funding: This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.

PROSPERO registration number: CRD42023431803

1 INTRODUCTION

Peripheral arterial disease (PAD) is associated with a high risk of atherothrombotic events (AE).[1, 2] The annual cardiovascular mortality risk of patients with intermittent claudication is approximately 5% compared to 11.5% for patients with critical limbthreatening ischemia.[3] In contrast to other atherosclerotic diseases such as coronary artery disease and cerebrovascular diseases, the overall long-term risk of major adverse cardiovascular events (MACE) of PAD patients is 2-fold worse.[4, 5] Last decades, revascularisation techniques have been improved which resulted in a 40% reduction in major lower limb amputations, however, the high cardiovascular mortality risk has barely declined.[1, 2, 6, 7]

A cornerstone in PAD MACE management is prevention through pharmacological therapies through lifelong antihypertensives, statins, and antithrombotic therapy (ATT).[1, 2, 8] Medication adherence (MA), which is the ability to take medication following prescriptions, is believed to be an essential factor for pharmacological therapies to be effective.[9, 10] However, approximately 50% of patients with long-term medication due to chronic diseases in developed countries have a poor MA.[11] More specifically, in patients with cardiovascular protective medicines, poor MA was found in 25-80%.[12-17] Nevertheless, the majority of these studies are outdated, focus on physician prescription adherence, primarily concentrate on patients without PAD diagnosis, or non-ATTs. MA is partly influenced by overarching factors such as healthcare systems, but many factors are disease- and patient-related such as clinical symptoms, socioeconomic background, and, medication side effects.[15, 18, 19] This underscores the importance of reporting on MA rates in specific patient populations and medication groups.

MA comprises two main elements: 'adherence' (or 'compliance') and 'persistence'. [9, 15]. No universally accepted consensus exists, however, adherence is mainly used to describe correct daily intake and persistence represents the continuation of daily intake.[9, 15] Adherence can be subdivided into primary- (or initiation) and secondary adherence to differentiate between the ability to initiate a new prescription and the daily intake after initiating the first prescription. Patients are mostly considered adherent when approximately 80% of the intake is as prescribed.[20, 21] MA is measured through patient- (questionnaires), pharmacy- (counting pills, refill records), or biochemical/laboratory-reported outcome measurements (Table S1).[22]

The optimal ATT in PAD patients is still under debate. [1, 8, 23, 24] MA is generally not discussed in trials although poor MA might lead to substantial bias and thus erroneous outcomes. As far as we know, there are no systematic analyses regarding MA of PAD patients to ATT. Therefore, we initiated this study to assess medication adherence specifically for ATT in patients with PAD.

(PRISMA)-statement

biochemical/laboratory-reported outcome

(incorrect

daily

(PROSPERO:

METHODS The protocol of this systematic review was based on the Preferred Reporting Items for Systematic Reviews and Meta-Analyses CRD42023431803).[25, 26] Search strategy and study selection The systematic literature search was performed from inception to June 7th, 2023. The bibliographic databases PubMed, Embase.com, and Wiley/Cochrane Library were used. The index terms "Peripheral Arterial Disease", "Antithrombotic Drugs", "Treatment Adherence and Compliance" along with their synonyms and/or closely related words, were included. The search was compiled by a medical database specialist (see Figures S1, S2, and S3). The search results were first deduplicated to which all obtained articles were screened on title and abstract by two independent researchers (EW and BM). Subsequently, the remaining articles were fully reviewed for eligibility and the references were screened for relevant publications (Figure S4). In case of disagreement, the study was reviewed by a third reviewer (CU). Eligible publications contained a (sub)population of adult PAD patients and reported on patients' (non)adherence and/or (non)persistence to ATT. Publications before the year 2000, review articles, expert opinions, case reports, use of polypills, only nurse-led intensified follow-up, and non-English articles were excluded (Figure S4). **Outcome definitions and measurements** The primary objective was the proportion of PAD patients with poor MA following patient-, pharmacy-, or measurements (Table S1). Poor MA includes; primary nonadherence (the inability to prescription), secondary nonadherence initiate а new dosage/timing/frequency after initiating a new prescription), and nonpersistence (discontinuation of the medication intake).[9, 15, 22] Secondary objectives were the proportion of PAD patients with (1) poor MA following pharmacy-reported outcome measurements, (2) primary nonadherence following pharmacy-reported- and (3) all outcome measurements, (4) secondary (short- and long-term) nonadherence following pharmacy-reported- and (5) all outcome measurements, and (6) nonpersistence following pharmacy-reported- and (7) all outcome measurements. Short-term was defined as a maximum follow-up of 6 months and long-term follow-up was defined as more than 6 months.
1 Data extraction and data analysis

The extracted data included; first author, year of publication, study design, country,
number of PAD patients, disease stage, mean age, male-female ratio, type of ATT, type
of MA subgroup(s), number of PAD patients that had poor MA per subgroup, number
of PAD patients with overlap between two or more MA subgroups, threshold for poor
MA, follow-up length, and MA outcome measurement.

The data were retrieved and collected in Review Manager Web (RevMan Web), version 4.14.0., The Cochrane Collaboration, Londen, UK. Based on the number of PAD patients with poor MA per subgroup and the total number of PAD patients, the proportions of nonadherence/nonpersistence were calculated per subgroup and processed in the table. For the primary objective, i.e. general poor MA, a separate calculation was made to adjust for patients with two or more kinds of poor MA to avoid overestimation of the general poor MA. Clinical homogeneity was assessed based on the study designs and definitions of nonadherence and/or non-persistence.

16 Quality assessment

The Cochrane Risk-of-Bias (ROB) tool was applied to assess the quality of the included randomised controlled trials (RCTs) that reported MA as primary outcome. The Cochrane ROB tool identifies different domains of bias and classifies risk into high-, low-, or unclear risk.[27] The overall quality was deemed high if all domains had a low ROB or if 1 domain was unclear. Unclear ROB was considered if $2 \ge$ domains were unclear and high ROB was assigned if $1 \ge$ domain had a high ROB. Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

For the non-RCTs and RCTs that report MA as a subanalysis, the methodological index for non-randomised studies (MINORS) score was used.[28] This method provides a 12-item list for comparative studies and an 8-item list for noncomparative studies. This score contains 3 classes; 0 (not reported), 1 (reported inadequate), and 2 (reported adequate). The overall quality for non-comparative trials was considered poor if the score was ≤ 8 , moderate between 9-14, and good if ≥ 15 . For the comparative trials, the score ranges were ≤ 15 , 16-22, and ≥ 23 .

31 Patient and public involvement

32 None

RESULTS

55 56 35 Screening process

The search identified 274 potentially relevant records after deduplicating. No articles were added by cross-linking. After reviewing the title and abstract, 227 articles were excluded and 4 articles could not be retrieved. The remaining 45 records were fully screened of which 10 records could be included; 6 RCTs, 2 prospective-, and 2
retrospective studies (Figure S1). In case of conflicting screening decisions, consensus
was reached between EW and BM.

5 Risk-of-bias assessment

6 Three articles were RCTs with MA as the main analysis of the trial and, therefore, the 7 Cochrane ROB tool was used (Table S2). The MINOR-score was used for the other 7 8 articles (Table S3). Overall, most studies had a moderate ROB. Concerns regarding the 9 ROB arise mostly due to patient-reported outcomes and non-adjudicated endpoints 10 that could be easily influenced by knowledge of the intervention. Moreover, most 11 articles did not calculate a sample size based on the MA outcome.

13 Study sample/study characteristics

The characteristics of the included studies are shown in Table 1. In total 32628 PAD patients were analysed. Most studies were executed in Europe, however, the two largest trials (EUCLID and VOYAGER PAD) that accounted for 63% of the included patients were executed in various countries and continents.[29, 30] MA was mostly reported as a sub-analysis. The included trials had rather heterogeneous study designs, making a meta-analysis infeasible.

1st Author, YOP	Country			ATT	Age	Female (%)	Follow-up	
		Sample size	Disease severity					
Randomised contro	lled trials							
	United Kingdom	67	R1-3 w EVR	A w C or PLB	Mn 66	15 (22)	1M	
Cassar 2006 [31]					(R: 43-80)			
	Sweden	105	R1-3 w EVR/SVR	Any ATT	Md 72	54 (52)	1,5Y	
Haile 2022 [32]					(IQR: 69-77)			
	Multiple	6564	R1-6 w EVR/SVR	ASA w PLB or DOAC	Mn 68	1704 (26)	Md 28M (IQR:	
Hess 2022 [30]					(IQR: 60-76)			
	Sweden	281	R4-6	ASA w PLB or LMWH	Mn 74	126 (45)	3M	
Jivegard 2005 [33]					(SD:9)			
	Denmark	2051	R 0-6 w/o EVR/SVR	Any ATT	Mn 70	0 (0)	5Y	
Qvist 2019 [34]					(SD: 2.9)			
	Multiple	13842	R1-6 w/o EVR/SVR	C or T	Mn 67	3884 (28)	30M (up to 42 I	
Weissler 2022 [29]					(IQR: 59-75)			
Prospective trials								
	Spain	194	NR	Any APT	Mn 64	43 (22)	1Y	
Ferreira 2010 [35]					(SD: 11.2)			
	Netherlands	246	R1-4	Any APT	Mn 69	105 (43)	1Y	
Kremers 2023 [36]					(SD: 9.2)			
Retrospective studie	es							
	United States	100	R1-6 w/o EVR/SVR	Any APT	Mn 64	42 (42)	NR	
Halle 2017 [37]					(SD: 9.5)			
	Slovak Republic	9178	R 0-6 w/o EVR/SVR	Any APT	Mn 75	5285 (58)	5Y	
Wawruch 2021 [38]								
Total		32628				11258 (35)		

APT = antiplatelet therapy; R = Rutherford classification; NR = not reported; EVR = endovascular revascularisation;

2	1	CVD survivel (see a survey derivetion Man second Mal survey) and the structure development of the second seco
4	1	SVR = surgical/open revascularisation; win = mean; wid = median; $R = range; \pm = standard deviation; () = percentage,$
5	2	M = Months, Y = years,
6	3	Table 1: Articles eligible for this systematic review
7	4	
8 9	5	Medication adherence
10	6	Poor MA following all outcome measurements ranged between 2-45% and following
11 12	7	pharmacy-reported measurements between 9-45% (Table 2). One study, however,
13	8	reported on all 3 subcategories of poor MA (i.e. primary-, secondary adherence, and
14 15	9	persistence) and reported a total risk of 33%.[34] Overall, higher proportions of poor
16	10	MA were found in studies with longer follow-ups, pharmacy-reported outcomes, and
17 18	11	registry-based methods.[32, 34, 38]
19	12	One study reported on primary nonadherence based on a pharmacy-reported
20 21	13	outcome measurement that occurred in 31% of the study population (Table 2). Short-
22	14	term secondary nonadherence was reported in 3 articles and ranged between 9-26%
23 24	15	(Table 2). Two of the 3 articles applied pharmacy-reported outcome measurement and
25 26	16	found rates between 9-21%. Long-term secondary nonadherence, described in 5

articles, showed rates ranging between 5-26% comparable to short-term secondary nonadherence (Table 2). Following the pharmacy-reported outcome measurement long-term secondary nonadherence occurred in 14-20% of the patients. Lastly, nonpersistence was found between 2-33% (Table 2). Nonpersistence within the pharmacy-reported group ranged between 27-33%. Higher rates of nonpersistence were found in studies with longer follow-ups and registry-based methods.

Enseignement Superieur (ABES) Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

Nr.	Reference	Nonadherence/ Nonpersistence	Follow-up	Measurement method	Threshold NA				
Poor medication adherence									
Pha	macy ROM	I	I	[
1	Cassar [31]	9%	1M	Counting returned pills	NR				
2	Haile [32]	30%	1,5Y	Counting pills	<80%				
3	Qvist [34]	45%*	5Y	National prescription register	Primary NA: filling prescription >120 days. Other: <80%				
4	Wawruch [38]	43%	5Y	Counting retuned pills	<80%				
Pha	macy- and patie	nt ROM							
5	Hess [30]	8%	Md 28M (IQR: 22-34)	Interview NVQ and counting returned pills	NR				
Patie	ent ROM								
6	Ferreira [35]	2%	1Y	Interview (NVQ)	NR				
7	Halle [37]	26%	NR	Morisky Medication Adherence Scale	8 Points				
8	Jivegard [33]	26%	3M	Patient dairy	NR				
9	Kremers [36]	5%	1Y	Morisky Medication Adherence Scale	8 Points				
10	Weissler [29]	10%	30M (up to 42 M)	Interview	NR				
		Pr	imary nonadherence						
1	Qvist [34]	31%	6M	National prescription register	Filling prescription >120 days				
		Sec	ondary nonadherence						
		Short-ter	m secondary nonadhere	ence					
Pha	macy ROM	I	1						
1	Cassar [31]	9%	1M	Counting returned pills	NR				
2 Patio	Haile [32] ent ROM	21%	6M	Counting pills	<80%				
1	Jivegard	26%	3M	Patient diary	NR				
		Long-1	term secondary outcom	e					
Pha	rmacy ROM								
1	Haile [32]	14%	1Y	Counting pills	<80%				
2	Qvist [34]	20%	5Y	National prescription register	<80%				
3	Wawruch [38]	20%	5Y	Counting returned pills	<80%				
Pati	ent ROM	·	-	· · · ·					
4	Halle [37]	26%	NR	Counting pills	<80%				
5	Kremers [36]	5%	1Y	Morisky Medication Adherence Scale	8 points				

			Nonpersistence**				
Pha	rmacy ROM						
1	Qvist [34]	27%	5Y	National prescription register	<80%		
2	Wawruch [38]	33%	5Y	Counting returned pills	<80%		
Pha	rmacy- and patie	nt ROM					
3	Hess [30]	8%	Md 28M (IQR 22-34)	Interview NVQ and counting returned pills	NR		
Patient ROM							
4	Ferreira [35]	2%	1Y	Interview (NVQ)	NR		
5	Weissler [29]	10%	30M (up to 42M)	Interview	NR		

• NR = not reported; Md = median; M = months; IQR = interquartile range; ROM = reported outcome measurements, NA = nonadherence, NVQ = non-validated questionnaire

* Nonpersistence is excluded since the proportion of the patients who were nonadherent and nonpersistent is lacking.

** Non-persistent due to patients' decisions.

Table 2: Medication adherence

DISCUSSION

10 This systematic review provides an overview of the literature about MA to ATT in 11 patients with PAD. The results demonstrate a poor MA rate of approximately one-third. 12 Despite the variability in poor MA rates, it shows the magnitude of poor MA. Higher 13 rates of poor MA were found in studies with longer follow-ups, pharmacy-reported 14 outcomes, and registry-based methods. The secondary objectives show that all 15 subcategories seem to have a nearly equal share in the overall risk of nonadherence. Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

Trial designs influence participant burdens which might partly explain the dispersion in MA amongst trials.[39, 40] In this review, 3 articles required minimum effort from participants because of the registry-based or retrospective design compared to the other articles including extensive follow-up, additional injections, and/or blood samples. Designs that required minimum effort, showed the highest rate of poor MA, nonadherence, and/or nonpersistence.[34, 37, 38] In the field of PAD, it is plausible that the likelihood of creating a more representative sample rises as the required effort for patients decreases. Literature shows that PAD patients are frequently precarious which is related to lower socioeconomic status and, therefore, less likely to participate in trials[12, 41-44] Reducing the complexity of trials leads to better understanding, fewer transfers, time commitment, and risk of additional (transfer) costs, resulting in a lower threshold for participation in this population.[40]

1 Regarding the length of follow-up, the literature shows a tendency for poor MA 2 to increase as the duration of medication use increases.[45-47] This review shows 3 similar results (Tables 2). One study provided a subanalysis (data not uptaken in our 4 tables) revealing that the highest proportion of nonadherence predominantly occurred 5 between 13 and 24 months with 44% and 35.5% respectively compared to 17% within 6 the first 12 months.[38] This pattern corresponds with the dispersion in our long-term 7 nonadherence results (Table 2).

8 Additionally, the heterogeneity of the reporting methods, such as the definition 9 of MA and outcome measurements, might contribute to the variety in proportions 10 between studies. MA includes 3 subcategories; primary nonadherence, secondary 11 nonadherence, and nonpersistence. Most articles, except one, researched only 12 nonpersistence and/or secondary nonadherence. This might underestimate the 13 proportion of poor MA by not identifying all categories of MA. The study that 14 distinguished all 3 subcategories reported the highest proportion of poor MA.[34]

Healthcare systems have a major influence on MA.[15, 18, 19, 41] One study
showed that participants from North America were more likely to discontinue their
medication compared to participants from Europe.[29] Another study executed in
North America confirmed that the inability to afford medication was a major reason for
poor MA.[37] Most European countries have similar healthcare systems that reimburse
necessary health costs.[48]

Regarding patient-related factors, studies that include post-revascularized PAD patients might show slightly higher MA rates.[30-32] One study showed lower long-term secondary nonadherence compared to short-term nonadherence.[32] These patients underwent revascularisation at 6 months follow-up. The severity of the symptoms might affect patients' perception of treatments. However, the literature is ambiguous.[37] Equivocal evidence regarding the impact of patient-related factors on MA is common. Amongst the included studies, subanalyses of patient-related factors show heterogeneous results.[29, 30, 35, 37, 38]

To estimate the individual risk of poor MA, it is of interest whether nonadherence leads to nonpersistence. It seems that adherent and nonadherence patients are both highly at risk for nonpersistence and thus poor MA.[38] The reason given is the lack of awareness regarding the life-long indication for ATT in PAD patients. We advise physicians to discuss MA with PAD patients. Additional research on all subcategories of MA based on registries that use pharmacy refill records and have extensive follow-up are warranted to confirm our findings.

The main strengths of this study are the selected inclusion of trials that include
 medication adherence of patients with PAD regarding antithrombotic therapies and

the distinction between different types of adherence which is clinically relevant when prescribing and discussing antithrombotic treatment. However, this review has a few limitations. Six out of the 10 included articles are RCTs. RCTs may not reflect real-world adherence as these patients are often more closely monitored, and therefore, more motivated. Most articles were at moderate risk for bias and a few studies did not mention its thresholds for non-adherence. Moreover, the heterogeneous study designs made a meta-analysis infeasible. Most of the included studies used patient-reported outcome measurements, i.e. questionnaires and interviews, which are at risk for multiple biases such as recall bias leading to potentially misleading low rates of poor MA.[13, 32, 49]

CONCLUSION

Studies regarding MA in PAD patients to ATT are scarce and contain heterogeneous designs creating a wide dispersion in MA proportions. However, poor MA to ATT was found in approximately one-third of the PAD patients and seemed to increase with longer duration of ATT use, which highlights the magnitude of this societal challenge.

AUTHOR CONTRIBUTIONS:

EW: Concept and design, screening, data collection, analyses and interpretation of data, writing of manuscript, final approval.

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

- BM: Screening, data collection, and analyses, final approval.
- CU: Concept and design, revision of manuscript, final approval.
- GJdB: Concept and design, revision of manuscript, final approval, and is the guarantor.

DATA STATEMENT:

- Access to the data is available via the correspondence of this article.

ETHICS APPROVAL:

Ethical approval was not considered as this review involved only previously published data.

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.

2			
3	1	REFE	ERENCES
4	2	1	Abovans V et al Editor's Choice - 2017 ESC Guidelines on the Diagnosis and Treatment of
5	2	1.	Perinheral Arterial Diseases in collaboration with the European Society for Vascular Surgery
7	4		(FSVS) Fur I Vasc Endovasc Surg 2018 55 (3): p. 305-368
, 8	5	2	Twine C.P. et al. Editor's Choice - European Society for Vascular Surgery (ESVS) 2023 Clinical
9	6	۷.	Practice Guidelines on Antithromhotic Therapy for Vascular Diseases, Eur I Vasc Endovasc
10	7		Surg 2023 65(5): n 627-689
11	2 2	3	van Haelst STW et al. Cardiovascular and all-cause mortality in natients with intermittent
12	0 0	Э.	claudication and critical limb ischaemia Br I Surg 2018 105 (3): p 252-261
13	10	Л	Welten G M et al. Long-term prognosis of nationts with peripheral arterial disease: a
14	11	4.	comparison in patients with coronary artery disease 1 Am Coll Cardiol 2008 51 (16): p. 1588-
15	12		06
10	12	5	Steg PG et al. One-year cardiovascular event rates in outpatients with atherothromhosis
18	14	Э.	1 Jamp = 2007 297 (11): p 1107-206
19	14	6	Barnes IA et al Enidemiology and Rick of Amnutation in Patients With Diabetes Mellitus
20	15	0.	and Perinheral Artery Disease Arterioscler Thromb Vasc Biol 2020 40 (8): p. 1808-1817
21	17	7	Voci D et al. Mortality rate related to peripheral arterial disease: A retrospective analysis of
22	18	/.	enidemiological data (years 2008-2010) Nutr Metab Cardiovasc Dis 2023 33 (3): p. 516-522
23	10	Q	Conto MS, et al. Society for Vascular Surgery practice guidelines for atheroscleratic
24	20	0.	occlusive disease of the lower extremities: management of asymptomatic disease and
25 26	20		claudication 1/Jase Surg 2015 61/3 Suppl): p. 2s-41s
20	21	٩	Cramer 1 A st al Medication compliance and persistence: terminology and definitions
28	22	5.	Value Health 2008 11(1): n 44-7
29	23	10	Simpson SH et al. A meta-analysis of the association between adherence to drug therapy
30	24	10.	and mortality Bmi 2006 222(7557): n 15
31	25	11	Sabaté E Adherence to long-term theranies: evidence for action 2003: World Health
32	20	11.	Organization
33	27	12	Baroletti S and H Dell'Orfano, Medication adherence in cardiovascular disease. Circulation
54 35	20	12.	2010 121 (12): n 1/155-8
36	30	13	Naderi S H. I.P. Bestwick and D.S. Wald Adherence to drugs that prevent cardiovascular
37	31	15.	disease: meta-analysis on 376 162 natients. Am I Med 2012 125 (9): n. 882-7 e1
38	32	14	Memon R A et al. Effect of the Polynill on Adherence and Prevention of Cardiovascular
39	33	14.	Diseases in Patients With or at High Risk of Cardiovascular Diseases: A Meta-Analysis of
40	34		Randomized Controlled Trials Cureus 2023 15(1): n e34134
41	35	15	Ho P.M. C.L. Bryson and LS Rumsfeld Medication adherence: its importance in
42	36	10.	cardiovascular outcomes Circulation 2009 119 (23): p 3028-35
45 44	37	16.	Flu, H C., et al., A systematic review of implementation of established recommended
45	38	10.	secondary prevention measures in patients with PAOD Fur I Vasc Endovasc Surg 2010, 39 (1):
46	39		n 70-86
47	40	17.	Chan, S.L., R. Raiesh, and T.Y. Tang. <i>Evidence-based medical treatment of peripheral arterial</i>
48	41	±7.	disease: A ranid review. Ann Acad Med Singan, 2021, 50 (5): p. 411-424
49	42	18	Kardas, P., P. Lewek, and M. Matyjaszczyk, Determinants of national adherence: a review of
50	43	10.	systematic reviews. Front Pharmacol. 2013. 4 : p. 91.
51	44	19.	Osterberg, L. and T. Blaschke, Adherence to medication. N Engl J Med. 2005. 353(5): p. 487-
52 52	45		97.
54	46	20	Svarstad, B.L., et al., The Brief Medication Questionnaire: a tool for screening natient
55	47	_0.	adherence and barriers to adherence. Patient Educ Couns. 1999 37 (2): n. 113-24
56	48	21	Karve, S., et al., Good and poor adherence: optimal cut-point for adherence measures using
57	49		administrative claims data. Curr Med Res Opin. 2009. 25(9): p. 2303-10.
58	50	22.	Lam. W.Y. and P. Fresco. <i>Medication Adherence Measures: An Overview</i> . Biomed Res Int.
59	51		2015. 2015 : p. 217047.
60	<u> </u>		P P

BMJ Open

2			
3	1	23.	Gerhard-Herman, M.D., et al., 2016 AHA/ACC Guideline on the Management of Patients with
4	2		Lower Extremity Peripheral Artery Disease: Executive Summary. Vasc Med, 2017. 22(3): p.
5	3		Np1-np43.
6	4	24.	Willems, L.H., et al., Antithrombotic Therapy for Symptomatic Peripheral Arterial Disease: A
/	5		Systematic Review and Network Meta-Analysis, Drugs, 2022, 82 (12); p. 1287-1302.
ð	6	25.	Page M.L. et al., PRISMA 2020 explanation and elaboration: undated auidance and
9 10	7	_0.	exemplars for reporting systematic reviews Bmi 2021 372 n n160
11	, 8	26	Rethlefsen M L et al PRISMA-S: an extension to the PRISMA Statement for Reporting
12	٥ ۵	20.	Literature Searches in Systematic Reviews Syst Rev 2021 10(1): n 30
13	10	77	Higging I.D. at al. The Cochrane Collaboration's tool for associating rick of higs in randomicad
14	10	27.	trials Dmi 2011 242 n dE028
15	11	20	(1/u/s. Dill), 2011. 343 . p. 03926.
16	12	28.	Silm, K., et al., <i>Wethodological index for non-randomized studies (minors): development and</i>
17	13	•••	validation of a new instrument. ANZ J Surg, 2003. 73 (9): p. 712-6.
18	14	29.	Weissler, E.H., et al., Understanding Study Drug Discontinuation Through EUCLID. Frontiers in
19	15		Cardiovascular Medicine, 2022. 9.
20	16	30.	Hess, C.N., et al., Sex-Based Differences in Outcomes Following Peripheral Artery
21	17		<i>Revascularization: Insights From VOYAGER PAD.</i> J Am Heart Assoc, 2022. 11 (12): p. e024655.
22	18	31.	Cassar, K., et al., Variability in Responsiveness to Clopidogrel in Patients with Intermittent
25 24	19		<i>Claudication</i> . European journal of vascular and endovascular surgery, 2006. 32 (1): p. 71-75.
24 25	20	32.	Haile, S.T., et al., Effects of a person-centred, nurse-led follow-up programme on adherence to
25	21		prescribed medication among patients surgically treated for intermittent claudication:
27	22		randomized clinical trial. Br J Surg, 2022. 109 (9): p. 846-856.
28	23	33.	Jivegård, L., et al., Effects of three months of low molecular weight heparin (dalteparin)
29	24		treatment after bypass surgery for lower limb ischemiaa randomised placebo-controlled
30	25		double blind multicentre trial. European journal of vascular and endovascular surgery, 2005.
31	26		29 (2): p. 190-198.
32	27	34.	Qvist, I., et al., Adherence to Prescribed Drugs Among 65-74 Year Old Men Diggnosed with
33	28		Abdominal Aortic Aneurysm or Peripheral Arterial Disease in a Screenina Trial: A VIVA
34	29		Substudy, Eur J Vasc Endovasc Surg. 2019, 57 (3): p. 442-450.
35	30	35	Ferreira-González L et al Background incidence and predictors of antiplatelet therapy
36	31	55.	discontinuation during the first year after drug-eluting stent implantation Circulation 2010
3/ 20	32		122 (10): n 1017-25
20 20	32	36	Kremers BMM et al Inadequate response to antiplatelet therapy in patients with
40	24	50.	norinheral artery diseases a prospective schort study. Thromb L 2022, 21 (1): p. 5
41	54 25	27	Hollo T. D., et al. Surgical Intervention for Derinberg Artery Disasse Dees Not Improve Datient
42	35	57.	Gampliance with Decomposed of Medical Therapy, App Medical Surg 2018, 46, p. 104, 111
43	30	20	Compliance with Recommended Medical Therapy. Ann Vasc Surg, 2018. 46 : p. 104-111.
44	37	38.	wawruch, M., et al., Adherence to Antiplatelet Medications among Persistent and Non-
45	38	20	Persistent Older Patients with Peripheral Arterial Disease. Biomedicines, 2021. 9(12).
46	39	39.	Cameron, D., et al., Assessing Participation Burden in Clinical Trials: Introducing the Patient
47	40		Friction Coefficient. Clin Ther, 2020. 42 (8): p. e150-e159.
48	41	40.	Getz, K., et al., Assessing Patient Participation Burden Based on Protocol Design
49	42		<i>Characteristics</i> . Ther Innov Regul Sci, 2020. 54 (3): p. 598-604.
50	43	41.	De Geest, S. and E. Sabaté, Adherence to long-term therapies: evidence for action. Eur J
51	44		Cardiovasc Nurs, 2003. 2 (4): p. 323.
52	45	42.	Joly, M., et al., Comparative evaluation of socioeconomic insecurity in peripheral and
54	46		coronary artery disease patients. J Med Vasc, 2022. 47(5-6): p. 220-227.
55	47	43.	Ohm, J., et al., Association of clinical trial participation after myocardial infarction with
56	48		socioeconomic status, clinical characteristics, and outcomes. Eur Heart J Open, 2021. 1(2): p.
57	49		oeab020.
58	50	44.	Chang, P., et al., Clinical and socioeconomic factors associated with unrecognized peripheral
59	51		artery disease. Vasc Med, 2014. 19 (4): p. 289-296.
60			

2	
2	
3	
4	
5	
2	
6	
7	
8	
0	
9	
10	
11	
11	
12	
13	
14	
17	
15	
16	
17	
10	
18	
19	
20	
20	
21	
22	
23	
24	
24	
25	
26	
27	
27	
28	
29	
20	
50	
31	
32	
22	
33	
34	
35	
26	
50	
37	
38	
20	
39	
40	
41	
⊿ ว	
-12	
43	
44	
45	
ر ب	
46	
47	
48	
40	
49	
50	
51	
51	
52	
53	
54	
55	
56	
57	
57	
58	

12 13

1

45. Krousel-Wood, M., et al., Predictors of decline in medication adherence: results from the 1 2 cohort study of medication adherence among older adults. Hypertension, 2011. 58(5): p. 804-3 10.

- 4 46. Newby, L.K., et al., Long-term adherence to evidence-based secondary prevention therapies in 5 coronary artery disease. Circulation, 2006. 113(2): p. 203-12.
- 6 Jackevicius, C.A., M. Mamdani, and J.V. Tu, Adherence with statin therapy in elderly patients 47. 7 with and without acute coronary syndromes. Jama, 2002. 288(4): p. 462-7.
- 8 Davis, K., et al., Mirror, mirror on the wall. How the performance of the US Health care 48. 9 system compares internationally. New York: CommonWealth Fund, 2014.
 - , A PROM. 10 49. Zini, M.L.L. and G. Banfi, A Narrative Literature Review of Bias in Collecting Patient Reported 11 Outcomes Measures (PROMs). Int J Environ Res Public Health, 2021. 18(23).

Enseignement Superieur (ABES) Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies

SUPPLEMENTARY FILE

Tables

Outcome measurements	Specification examples [description]*		
pharmacist-reported outcome measurements	Medication Event Monitoring System (MEMS) [Use		
	of electronic devices with microchips to record		
	medication intake]		
	Pharmacy records [Counting returned pills and		
	tracking refill patterns]		
	Prescription records registers [Tracking all		
	dispensed drugs and tracking refill patterns]		
Patient-reported outcome measurements	Morisky Medication Adherence Scale (MMAS-8)[1]		
	Medication Adherence Report Scale (MARS)[2]		
	Simplified Medication Adherence Questionnaire		
	(SMAQ)[3]		
	Brief Medication Questionnaire (BMQ)[4]		
	Other		
Biochemical or laboratory outcome	INR, Platelet activity		
measurements			

• * This table does not include all existing measurements.

Table S1: Outcome measurements







For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

Cassar, 2006 [8]	2	2	2	2	1	1	2	0	1	2	1	2	18/2 4	Μ
Ferreira, 2010 [9]	2	0	2	2	0	2	0	0	N/A	N/A	N/A	N/A	8/16	Ρ
Halle, 2017 [10]	2	2	2	2	1	1	2	0	N/A	N/A	N/A	N/A	12/1 6	Μ
Hess, 2022 [11]	1	1	2	1	1	2	2	0	N/A	N/A	N/A	N/A	10/1 6	М
Kremers, 2023 [12]	2	1	2	2	1	2	2	0	N/A	N/A	N/A	N/A	12/1 6	Μ
Qvist, 2019 [13]	2	1	1	2	2	2	2	0	N/A	N/A	N/A	N/A	12/1 6	Μ
Wawruch, 2021 [14]	2	2	1	2	2	2	2	0	N/A	N/A	N/A	N/A	13/1 6	Μ

N/A = not applicable; P = Poor; M = Moderate; G = good

Table S3. Risk-of-bias of bias summary for the non-randomised controlled trials following the MINORs-score

Per terier on

Enseignement Superieur (ABES) Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.

Figures

Search	Actions	Details	Query	Results	Time
#4		•	Search: #1 AND #2 AND #3 Sort by: Most Recent	128	08:50:30
#3		•	Search: "Treatment Adherence and Compliance"[Mesh] OR "Medication Adherence"[Mesh]] OR "compliance" [tiab] OR "adherence" [tiab] OR "refus*"[tiab] OR "nonadherence"[tiab] OR "noncompliance"[tiab] Sort by: Most Recent	542,177	08:50:03
#2		• >	Search: "Platelet Aggregation Inhibitors" [Mesh] OR "Platelet Aggregation Inhibitors" [Pharmacological Action] OR "Dual Anti- Platelet Therapy" [Mesh] OR "Platelet aggregation inhibitor*" [tiab] OR "antiplatelet theraps" [tiab] OR "anti platelet theraps" [tiab] OR OR "platelet inhibitor*" [tiab] OR "platelet aggregant*" [tiab] OR "acetylsalicylic acid" [tiab] OR "aspirin" [tiab] OR "paracetamol" [tiab] OR "clopidogrel" [tiab] OR OR "Anticoagulants" [Mesh] OR "Anticoagulants" [Pharmacological Action] OR "Indirect thrombin inhibitor*" [tiab] OR "anti coagulant" [tiab] OR "Fibrinolytic Agents" [Mesh] OR "fibrinolytic agent*" [tiab] OR "fibrinolytic drug*" [tiab] OR "Thrombolytic drug*" [tiab] OR "antithrombotic agent*" [tiab] OR "antithrombotic drug*" [tiab] OR "antithrombotic agent*" [tiab] OR "anticoagulant*" [tiab] OR "Factor Xa inhibitor*" [tiab] OR "Rivaroxaban" [tiab] Sort by: Most Recent	468,945	08:49:49
#1		>	Search: ("Peripheral Arterial Disease" [Mesh] OR "peripheral arterial disease*" [tiab] OR "peripheral artery disease*" [tiab] OR "lower extremity arterial disease*" [tiab] OR "lower extremity artery disease*" [tiab] OR "Chronic Limb-Threatening Ischemia*" [tiab] OR "intermittent claudication*" [tiab] OR "Peripheral Arterial Vascular Disease*" [tiab] OR "peripheral artery occlusive disease*" [tiab] OR "peripheral arterial occlusive disease*" [tiab] AND ("Peripheral Arterial Disease" [Mesh] OR "peripheral arterial disease*" [tiab] OR "peripheral artery disease*" [tiab] OR "lower extremity arterial disease*" [tiab] OR "lower extremity artery disease*" [tiab] OR "Chronic Limb-Threatening Ischemia*" [tiab] OR "intermittent claudication*" [tiab] OR "Peripheral Arterial Vascular Disease*" [tiab] OR "peripheral artery occlusive disease*" [tiab] OR "Chronic Limb-Threatening Ischemia*" [tiab] OR "peripheral arterial occlusive disease*" [tiab] Sort by: Most Recent	32,848	08:44:08

Figure S1. Search PubMed/MEDLINE



Enseignement Superieur (ABES) Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.



BMJ Open

Enseignement Superieur (ABES) Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.



Figure S3. Search in Embase



Figure S4. The flowchart of the selection process

- 1. Morisky, D.E., et al., *Predictive validity of a medication adherence measure in an outpatient setting.* J Clin Hypertens (Greenwich), 2008. **10**(5): p. 348-54.
- Baroletti, S. and H. Dell'Orfano, *Medication adherence in cardiovascular disease*. Circulation, 2010. **121**(12): p. 1455-8.
- 3. Knobel, H., et al., *Validation of a simplified medication adherence questionnaire in a large cohort of HIV-infected patients: the GEEMA Study.* Aids, 2002. **16**(4): p. 605-13.
- 4. Svarstad, B.L., et al., *The Brief Medication Questionnaire: a tool for screening patient adherence and barriers to adherence.* Patient Educ Couns, 1999. **37**(2): p. 113-24.
- 5. Haile, S.T., et al., *Effects of a person-centred, nurse-led follow-up programme on adherence to prescribed medication among patients surgically treated for intermittent claudication: randomized clinical trial.* Br J Surg, 2022. **109**(9): p. 846-856.

29(2): p. 190-198.

122(10): p. 1017-25.

Cardiovascular Medicine, 2022. 9.

Jivegård, L., et al., *Effects of three months of low molecular weight heparin (dalteparin) treatment after bypass surgery for lower limb ischemia--a randomised placebo-controlled double blind multicentre trial.* European journal of vascular and endovascular surgery, 2005.

Weissler, E.H., et al., Understanding Study Drug Discontinuation Through EUCLID. Frontiers in

Cassar, K., et al., *Variability in Responsiveness to Clopidogrel in Patients with Intermittent Claudication*. European journal of vascular and endovascular surgery, 2006. **32**(1): p. 71-75.

Ferreira-González, I., et al., Background, incidence, and predictors of antiplatelet therapy discontinuation during the first year after drug-eluting stent implantation. Circulation, 2010.

Halle, T.R., et al., Surgical Intervention for Peripheral Artery Disease Does Not Improve Patient

Hess, C.N., et al., *Sex-Based Differences in Outcomes Following Peripheral Artery Revascularization: Insights From VOYAGER PAD.* J Am Heart Assoc, 2022. **11**(12): p. e024655.

Kremers, B.M.M., et al., Inadequate response to antiplatelet therapy in patients with peripheral

Qvist, I., et al., Adherence to Prescribed Drugs Among 65-74 Year Old Men Diagnosed with Abdominal Aortic Aneurysm or Peripheral Arterial Disease in a Screening Trial: A VIVA Substudy.

Wawruch, M., et al., Adherence to Antiplatelet Medications among Persistent and Non-

Persistent Older Patients with Peripheral Arterial Disease. Biomedicines, 2021. 9(12).

Compliance with Recommended Medical Therapy. Ann Vasc Surg, 2018. **46**: p. 104-111.

artery disease: a prospective cohort study. Thromb J, 2023. 21(1): p. 5.

Eur J Vasc Endovasc Surg, 2019. 57(3): p. 442-450.

1 2 3 4 5 6	6.
7 8	7.
9 10 11	8.
12 13 14	9.
15 16	10.
17 18	11.
19 20 21	12.
21 22 23 24	13.
23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51	13.
52 53 54 55 56 57	
58	

59 60

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml